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THESIS ABSTRACT 
 
This thesis is comprised of studies of proteins involved in class I and class II 
major histocompatibility complex (MHC) antigen procressing. In class I MHC 
processing, structural and functional studies were conducted of an 
aminopeptidase, ERAP1, that mediates the final step in antigen processing to 
understand how it is particularly suitable for cleavage of antigenic peptides for 
class I MHC presentation. In the class II MHC antigen presentation pathway, 
structural studies were conducted to characterize a fluorogenic peptide that can 
be used to understand peptide loading events in vivo and in real time. Also 
structural studies of class II MHC and peptide complexes were conducted to 
understand the nature of an unique C-terminal secondary structure element 
exhibited by an HIV derived peptide in the peptide binding groove of class II 
MHC. The studies discussed in this thesis provide insights into the proteins 
involved in the class I and class II MHC antigen presentation pathway. 
The endoplasmic reticulum (ER) aminopeptidase, ERAP1, is a 941 amino 
acid member of the M1 family of zinc metalloaminopeptidases. Unlike other 
aminopeptidases, ERAP1 has a length and C-terminal preference for its 
substrates. Interestingly, ERAP1 has been shown to trim antigenic peptides to 
lengths of 8 or 9 amino acids long. This length matches the length required to 
bind into the peptide binding groove of class I MHC molecules. In addition, 
ERAP1 is upregulated in the ER of cells treated with interferon gamma (IFN-γ). 
v 
Knock-down of ERAP1 by siRNA results in less overall antigenic presentation 
during IFN-γ treatment, although the knock-down does not affect all class I MHC 
epitopes equally. Knock-out studies show that ERAP1 effects the antigen 
repertoire at the cell surface. These and other data implicate ERAP1 as an 
important player in class I MHC antigen presentation. A chapter of this thesis will 
describe the crystallographic work describing the structures of ERAP1 with an 
aminopeptidase inhibitor, bestatin, and ERAP1 without an inhibitor that suggest 
possible peptide binding site in ERAP1 that will allow it to generate suitable 
substrates for a subset of class I MHC alleles.  
Class II MHC plays a key role in the immune response by presenting 
antigenic peptides on CD4+ cytotoxic cell surfaces for T-cell response. The 
binding of peptides onto the MHC is an important step in creating an immune 
response. Structures of peptide bound MHC class II show conserved side chain 
binding pockets within the overall peptide-binding groove.  In HLA-DR1, a 
common human class II MHC, the P1 pocket shows a preference for large 
hydrophobic side chains. Development of environmentally sensitive peptide 
analogs, that can bind into the class II MHC the same way as native peptides, 
can assist in visualizing the antigen binding process. A chapter in this thesis 
describes the crystallographic work showing that (4-DAPA)-HA can be used to 
study antigen-presenting processes in a cell by visualizing the changes in 
fluorescence of the synthesized peptide upon antigen loading. 
vi 
Crystallographic analysis of MHC class II, HLA-DR1, in complex with HIV 
gag-derived peptide, GagP16(PEVIPMFSALSEGATP), and superantigen, SEC3-
3B2, reveals the conventional polyproline conformation up to MHC binding 
pocket residue, P9, while the C-terminus of GagP16 adopts an unusual β- hairpin 
loop structure. Additionally, interactions between the leucine at P8 (LeuP8) and 
other residues on the loop such as ThrP16 and AlaP14 of the hairpin loop, was 
observed. Importantly, GagP16 requires the last 4 amino acids (P13-P16), which 
is part of the hairpin loop, for T-cell recognition. Understanding what dictates the 
C-terminal hairpin loop and the interaction motif of HLA-DR1/GagP16 complex 
with its TCR will provide insights on why it is important for T cell activation. A 
chapter in this thesis discusses the structural investigation conducted to 
understand the determinants of the loop at the C-terminus of GagP16 using 
designed peptides. It will also discuss work involving HLA-DR1 with the T cell 
receptor, AC25, that was cloned from T cells that are specific to HLA-DR1 in 
complex with the GagP16 peptide. 
vii 
TABLE OF CONTENTS 
 
Title Page i 
Signature Page ii 
Acknowledgements iii 
Abstract iv 
Table of Contents vii 
List of Tables x 
List of Figures xi 
Abbreviations xiv 
Prefaces xv 
 
Chapter I 
Introduction  
Overview of Studies in Thesis 1 
Overview of the Immune System 1 
Structural Features of Class I MHC 6 
Class I MHC Antigen Processing and Presentation Pathway 10 
Class I MHC Antigen Loading Complex 12 
The ER Aminopeptidase, ERAP1 13 
M1 Family of Aminopeptidases 15 
The Oxytocinase Subfamily M1 Family of Aminopeptidases 20 
viii 
Structural Features of Class II MHC 22 
Class II MHC Antigen Processing Pathway 28 
MHC/Peptide and TCR Mode of Interactions 29 
Studies in This Thesis 36 
 
Chapter II 
Structural Basis for Antigenic Peptide Precursor Trimming by 
ERAP1, The Endoplasmic Reticulum Aminopeptidase Involved in 
Antigen Processing 
 
Introduction 37 
Materials and Methods 41 
Results 44 
Discussion 94 
 
Chapter III 
Structural Analysis of MHCII, HLA-­‐DR1, in Complex with an Environmentally
Sensitive Peptide, (4-­‐DAPA)-­‐HA 
 
Introduction 103 
Materials and Methods 105 
Results 111 
Discussion 124 
  
ix 
 
Chapter IV 
Structural Study on the Determinants of the C-terminal Hairpin Loop 
of the GagP16 Peptide in the Binding Groove of HLA-DR1 
 
Introduction 127 
Materials and Methods 130 
Results 136 
Discussion 154 
  
 
Chapter V 
Conclusions and Future Directions 159 
 
Appendices 167 
  
References 202 
  
 
 
 
x 
List of Tables 
 
 
 
 
 
Table 2.1 Data Collection and Refinement Statistics for ERAP1 49 
   
Table 3.1 Data Collection and Refinement Statistics for DR1/ 
(4-DAPA)-HA 
126 
   
Table 4.1 Data Collection and Refinement Statistics for DR1/Hybrid 
Peptides 
157 
   
Table 4.2 Data Collection Statistics for AC25scTCR with 
DR1/GagP16 
158 
   
   
   
 
xi 
List of Figures 
 
 
Figure 1.1 Illustration of MHC Antigen Loading Pathways 4 
Figure 1.2 Class I And Class II MHC are Structurally Homologous 8 
Figure 1.3 Structure of Representative M1 Aminopeptidase Family 
Member, M1 Alanylaminopeptidase From Malaria 
19 
Figure 1.4 Sequence Alignment of Human ERAP1, ERAP2, and IRAP 21 
Figure 1.5 Class I and Class II MHC Main Chain with Peptide 
Interaction 
24 
Figure 1.6 Peptide Binding Pockets in Class I and Class II MHC 26 
Figure 1.7 Modes of Interaction Between α/β TCR and Class II MHC 31 
Figure 1.8 HIV Gag Derived Peptides in Class II MHC 34 
   
Figure 2.1 Structure Based Alignment M1 Aminopeptidase Family 
Members 
46 
Figure 2.2 ERAP1 Trimer in the Crystallographic Asymmetric Unit 50 
Figure 2.3 Electron Density of ERAP1 52 
Figure 2.4 Structure of ERAP1 55 
Figure 2.5 Schematic Diagram of the C-Terminal Domain of ERAP1 57 
Figure 2.6 Large Cavity Formed by the Catalytic Domain II and C-
Terminal Domain IV 
60 
Figure 2.7 The Active Site of ERAP1 64 
xii 
Figure 2.8 The Inhibitor Inside ERAP1 Active Site 66 
Figure 2.9 Conservation of Catalytic Residues Among M1 Family 
Aminopeptidase Structures 
69 
Figure 2.10 Surface Polarity of ERAP1 in the Substrate Binding Site 72 
Figure 2.11 Electrostatic Surface Map of ERAP1 77 
Figure 2.12 Overall Fold of M1 Family of Aminopeptidases 80 
Figure 2.13 Domain Movements 83 
Figure 2.14 Allosteric Activation of ERAP1 87 
Figure 2.15 Ankylosing Spondylitis- Associated Mutations Mapped on 
Surface of ERAP1 
92 
Figure 2.16 Open and Closed Conformations of ERAP1 98 
   
Figure 3.1 The (4-DAPA)-HA Peptide Exhibits a Spectral Shift when 
Bound to HLA-DR1 
114 
Figure 3.2 The (4-DAPA)-HA Peptide Stimulates HA Specific T Cells 
Similarly as Compared to Native HA Peptide 
116 
Figure 3.3 The (4-DAPA)-HA Binds into HLA-DR1 in the Same 
Register as the Native HA Peptide 
118 
Figure 3.4 The 4-DAPA Binds into the P1 Pocket 120 
Figure 3.5 Maldi-TOF Mass Spectrometry Spectra of Peptide Eluted 
from HLA-DR1/(4-DAPA)-HA Peptide/SEC3-3b2 Crystals  
122 
   
xiii 
Figure 4.1 Electron Density of Hybrid 1 Peptide in Binding Groove 139 
Figure 4.2 Electron Density of Hybrid 2 Peptide in Binding Groove 141 
Figure 4.3 Electron Density of Hybrid 3 Peptide in Binding Groove 143 
Figure 4.4 AC25 Single Chain TCR Purifies as a Monomer 147 
Figure 4.5 Thermal Melt of AC25 Single Chain TCR Observed by 
Circular Dichroism 
149 
Figure 4.6 Surface Plasmon Resonance Does Not Detect Interaction 
Between AC25scTCR and HLA-DR1/GagP16 
150 
Figure 4.7 Crystal Packing of HLA-DR1/GagP16 152 
   
 
xiv 
Abbreviations 
 
MHC - major histocompatibility complex 
HLA- human leukocyte antigen 
CLIP- Class II-associated invariant chain 
TCR- T cell receptor 
T cells- T lymphocytes 
B cells- B lymphocytes 
IRAP- Insulin regulated aminopeptidase 
ERAP- Endoplasmic reticulum aminopeptidase 
DAPA- 4-N,N,-dimethylaminophthalimidoalanine 
HA- Influenza-derived peptide residues 306-PKYVKQNTLKLAT-318 
GagP16- Gag caspid derived peptide residues 34-PEVIPMFSALEGATP-48 
APC- Antigen presenting cell 
IFN- Interferon 
HC- Heavy chain 
IgG- Immunogloblin type G 
TAP- transporter associated with antigen processing 
β2M- β2 microglobulin 
 
xv 
Preface 
 
 
 
The work presented in chapter II on structural characterization of ERAP1 was 
done in collaboration with the laboratories of Efstratios Stratikos and Alfred 
Goldberg, who provided biochemical data. 
 
The worked presented in chapter III on the characterizing the fluorogenic peptide, 
(4-DAPA)-HA was done in collaboration with a former Stern lab member, 
Prassana Venkatraman, Mauricio Calle-Calvo and the laboratory of Barbara 
Imperiali. The fluorophore (4-DAPA) was provided by the Imperiali lab and 
Prassana Venkatraman incorporated (4-DAPA) into the HA peptide and 
characterized the its spectroscopic activity when in complex with HLA-DR1 
(Figure 3. 1). Mauricio Calle-Calvo executed the Il-2 bioassay with me (Figure 
3.2). 
 
References 
 
Nguyen TT, Chang SC, Evnouchidou I, York IA, Zikos C, Rock KL, Goldberg AL, 
Stratikos E, Stern LJ., Structural Basis For Antigenic Peptide Precursor 
Processing by the Endoplasmic Reticulum Aminopeptidase ERAP1, Manuscript 
Submitted.  
 
 
Venkatraman P, Nguyen TT, Sainlos M, Bilsel O, Chitta S, Imperiali B, Stern LJ. 
Fluorogenic probes for monitoring peptide binding to class II MHC proteins in 
living cells. Nat Chem Biol. 2007 Apr;3(4):222-8.  
 
 
1CHAPTER 1 
INTRODUCTION 
 
Overview of Studies in Thesis 
The focus of this thesis is on the molecules involved in the peptide antigen 
processing for loading onto the major histocompatibility complex (MHC) that is 
important for activation of T- lymphocytes (T cells). It will include structural 
characterization of an endoplasmic reticulum aminopeptidase, ERAP1, a 
fluorogenic peptide, (4-DAPA)-HA, that can be used for visualizing peptide 
loading only MHC molecules, and peptide MHC complexes that was designed to 
understand an unique C-terminal hairpin structure exhibited by an HIV derived 
peptide in the context of MHC molecules. These studies provide further structural 
understanding of the molecules involved in antigen presentation. 
 
Overview of the Immune System 
The immune system defends vertebrates from foreign agents by 
differentiating between self and non-self, and then responding to eliminate non-
self. It plays a major role in many health conditions such as tumor recognition, 
autoimmunity, grafted organ acceptance, allergies and protection against 
infectious agents. Immune responses can be categorized as innate or adaptive 
responses. The innate immune system recognizes and responds to conserved 
microbial pathogen-associated molecular patterns such as lipopolysaccharide, 
2and results in immediate effects such as inflammation. The adaptive immune 
system, also referred to as the specific immune system, is slower to respond 
relative to the innate immune system, but is more selective, and can “learn” to 
recognize extremely varied antigens with great specificity.  B- lymphocytes (B 
cells) recognize epitopes directly via their clonotypic B cell receptors that can be 
secreted in soluble form as soluble antibodies, as in the case of neutralizing 
antibodies. T cells, however, recognize foreign pathogens that are presented on 
the surface of other cells through presenter molecules such as MHC proteins 
(Janeway, 2001). 
In the adaptive immune system, antigen presenting cells (APC) present 
antigens such as peptides, DNA or carbohydrates on the cell surface for T cell 
recognition and elimination. T cells are categorized based on their expression of 
one of two glycoprotein surface markers, CD8 or CD4. T cells expressing the 
CD4 surface marker (“Helper” T cells) generally release cytokines and 
chemokines upon recognition of specific antigen, resulting in recruitment and 
activation of macrophages for phagocytosis, and stimulation B cells for antibody 
production against the antigen recognized. T cells expressing the CD8 surface 
marker generally play a cytotoxic role and recognize cells presenting non-self 
antigens and directly eliminate those cells. However, some CD4 expressing T 
cells were shown to have cytotoxic roles and some CD8 expressing T cells 
secrete cytokines (Janeway, 2001). 
3T cell antigen recognition is mediated by antigen presenting molecules, 
MHC proteins, that present self and non-self peptides on the surface of APCs. 
CD4+ T cells recognize class II MHC molecules and CD8+ T cells recognize 
class I MHC molecules. While both classes of MHC molecules present peptides 
on the cell surface, they differ structurally, in peptide binding specificity, in 
peptide antigen processing pathways and in their source of peptide antigens 
(Braciale et al., 1987a; Madden, 1995; Stern et al., 1994). Both classes of MHC 
are loaded with peptide epitopes through a multi-step process that includes 
folding in the endoplasmic reticulum (ER), trafficking through the Golgi apparatus 
and presentation on the cell surface for T cell recognition. In general, for both 
class I and class II MHC complexes, antigen must be processed to be suitable 
for loading onto the MHC molecules, and the nascent MHC molecules must be 
matured into a receptive state for loading the antigens (Figure 1.1) (Braciale et 
al., 1987b).  
4 
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Figure 1.1. Illustration of MHC Antigen Loading Pathways. Left side shows 
class I MHC peptide loading pathway where a polypeptide in the cytosol is 
cleaved by the proteasome into shorter peptides. The peptides are transported 
into the endoplasmic reticulum by TAP transporter molecules where peptides can 
bind into class II MHC molecules. Empty class I MHC molecules interact with 
members of the antigen loading complex, tapasin, ERp57 and calreticulum in the 
ER. Longer peptides can be further trimmed by ER aminopeptidases, ERAP1 
and/or ERAP2 before MHC loading. Class I MHC bound to a peptide dissociates 
from the loading complex are transported through the Golgi apparatus to the cell 
surface for CD8+ T cell recognition. Right side shows the class II MHC peptide 
loading pathway where foreign proteins are endocytosed into the cell through 
endosomes which fuses with the lysosome where polypeptides can be cleaved 
into peptides by low pH activated proteases. Next the endosome merges with 
exocytic vesicles that carry class II MHC associated with the invariant chain. The 
invariant chain gets cleaved to a shorter CLIP peptide, which occupies the 
peptide binding groove of class II MHC until HLA-DM that is regulated by HLA-
DO assists peptide loading onto class II MHC in the merged endosomes. Peptide 
bound class II MHC then gets transported to the cell surface for CD4+ T cell 
recognition. 
6Structural Features of Class I MHC 
Class I MHC molecules present self and foreign peptide antigens for 
CD8+ cytotoxic T cell recognition. Class I MHC molecules are heterodimers 
consisting of a polymorphic heavy chain (HC) and a monomorphic 
immunoglobulin (IgG) like light chain (β2M). HC is a glycoprotein that consists of 
4 domains: α1 and α2 make up the peptide binding groove for antigens, α3 is a 
membrane-proximal IgG-like domain and the fourth domain consist of a C-
terminal transmembrane domain and a short cytoplasmic tail (Korman et al., 
1982; Orr et al., 1979; Townsend et al., 1990). The light chain β2M is not 
membrane-bound; non-covalent interactions between HC and β2M stabilize upon 
peptide binding (Figure 1.2) (Townsend et al., 1990). Peptides that bind into the 
binding groove are typically 8-10 amino acids in length, usually with a positively 
charged or hydrophobic C-terminal residue (Rammensee et al., 1995). Pockets 
along the length of the peptide binding groove provide further peptide sequence 
specificity (Collins et al., 1995; Mattson et al., 1989). Since the MHC gene is 
highly polymorphic, different class I MHC alleles may vary in peptide binding 
specificity because a majority of the polymorphic amino acids are in the peptide 
binding groove (Parham et al., 1989).  For example, two mouse class I MHC 
alleles, H2-Kd and H2-Kb, exhibit different peptide specificities. H2-Kd binds 9-
mers and prefers the amino acids, TYR or PHE, at the 8th position from the C-
terminus which like H2-Kb prefers positively charged or hydrophobic amino acids 
(for example, Y/FXXXXXX-positive/hydrophobic) (Falk et al., 1991).  H2-Kb binds 
78-mers and prefers TYR or PHE at the 4th position from the C-terminus (for 
example, XXXXY/FXX-positive/hydrophobic), but shows no preference for a 
particular amino acid at the 8th position like that observed in H2-Kd (Falk et al., 
1991; Rammensee, 1995). Unlike class II MHC, class I MHC binds to its peptide 
substrate in a way that the both N- and C- terminus of the peptide are in the 
pockets of the class I MHC (Bjorkman et al., 1987; Stern et al., 1994). 
8 
9Figure 1.2. Class I and Class II MHC are Structurally Homologous. MHC 
molecules are represented in ribbon diagram. Left side shows a class I MHC 
molecule heavy chain is green and β2M is cyan. The class I molecule, H2-Kb, is 
bound to the ovalbumin derived peptide, SIINFEKL (PDB 1VAC). Right side 
panel shows a class II MHC molecule. The α chain is green and β chain is cyan. 
The class II molecule, HLA-DR1, is bound to the influenza hemagglutinin derived 
peptide, HA (PDB 1DLH). Peptides in both molecules are shown in magenta 
cartoon. 
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Class I MHC Antigen Processing and Presentation Pathway 
  Class I MHC loading requires two elements to come together: first, the 
nascent class I MHC molecule is synthesized in the ER stabilized by the antigen 
loading complex; and second, cytosolic proteins must be proteolized by the 
proteasome and transported into the ER for further trimming and presentation  
(Figure 1.1). Many of the proteins involved in this pathway are upregulated upon 
cytokine stimulation (Aki et al., 1994; Klar and Hammerling, 1989; Saric et al., 
2002). Modulation of proteins in this pathway can result in changes in the cell 
surface antigen repertoire and can influence T cell response (Boulanger et al., 
2010; Garbi et al., 2000; York et al., 2006). For example, herpes simplex virus, 
HSV, can inhibit a crucial transporter protein, TAP, involved in transporting 
antigen precursors into the ER.  This reduces the ability of the infected cell to 
present HSV protein epitopes bound to class I MHC on their surface for T cells to 
detect (Galocha et al., 1997). 
Class I MHC antigen processing begins in the cytosol where the 
proteasome subunits β1, β2, β5 are replaced by β1i, β2i and β5i, resulting in a 
proteasome termed the “immunoproteasome” because of its different enzymatic 
activity (Aki et al., 1994; Frentzel et al., 1994). The immunoproteasome was 
shown to produce more N-extended (9-15 residues) peptides compared to the 
proteasome (Cascio et al., 2001). Additionally, in studies using the ovalbumin 
derived peptide, SIINFEKL, the C-termini of peptide antigens are formed in the 
cytosol by the proteasome (Cascio et al., 2001; Craiu et al., 1997).  When the 
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immunoproteasome peptide products are not degraded in the cytosol by other 
peptidases such as leucine aminopeptidase into single amino acids, the peptides 
can be transported into the ER by an ATP dependent transporter, transporter 
associated with antigen processing (TAP), which is also upregulated upon 
cytokine stimulation (Bacik et al., 1994; Beninga et al., 1998; Reits et al., 2004).  
TAP can transport peptides that are at 8-16 residues long but prefers 9-12 
residues peptides (Schumacher et al., 1994; van Endert et al., 1994).  Similar to 
class I MHC molecules and the aminopeptidase ERAP1, TAP prefers to transport 
peptides with a hydrophobic or arginine C- terminal residues (F, L, R, Y, V) 
(Uebel and Tampe, 1999). N-extended peptides in the ER require further 
processing before loading onto class I MHC. Inside the ER, peptide antigen can 
be further trimmed from the amino terminus to the suitable size of 8-10 amino 
acids by the M1 family of aminopeptidase members, ERAP1 or ERAP2 (Saric et 
al., 2002; Tanioka et al., 2003; York et al., 2002). Even though not all antigens 
require further processing in the ER, a majority of peptides entering the ER 
through TAP will need further processing because of the specificity of TAP for 
peptides of at least 8 residues and the production of longer peptides by the 
immunoproteasome (Cascio et al., 2001; Schumacher et al., 1994). The peptide 
bound class I MHC complex is released from the antigen loading complex and 
processed through the Golgi apparatus for presentation on the cell surface for 
CD8+ T cell recognition.  
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Class I MHC Antigen Loading Complex 
Newly synthesized class I MHC in the ER associates with the loading 
complex before a peptide is loaded, and the peptide-MHC complex is transported 
to the cell surface. It was shown that before peptide loading onto class I MHC 
molecules, HC and β2M interact with ER chaperones, calreticulin or calnexin, as 
well as with the protein sulfide isomerase family member, ERp57 (Degen and 
Williams, 1991; Morrice and Powis, 1998). Calnexin is a membrane bound 
chaperone that interacts with nascent HC before the closely related soluble 
chaperone binds (Kang et al., 2009). The chaperones have been shown to 
interact with HC through their lectin like domains and stabilize HC with β2-m 
(Degen and Williams, 1991; Leach et al., 2002). ERp57 is a member of the PDI 
family and is composed of four thioredoxin domains, of which only two contain an 
active site motif and was shown to affect the rate of disulfide bond formation in 
HC (Dick et al., 2002). It was suggested that upon antigen binding, conserved 
Cys 101 and 164 in the peptide binding site of HC are shielded from ERp57 
reduction (Dick et al., 2002). However, it is unclear what redox activities are 
involved in the loading of antigen onto class I MHC molecules. HC was, also 
shown to be, tethered to TAP by a membrane bound protein, tapasin (Suh et al., 
1999).  Tapasin was proposed to be a peptide editor for class I MHC and to 
assist in peptide loading (Garbi et al., 2000; Momburg and Tan, 2002). HC, β2M, 
TAP, tapasin, ERp57 and calreticulin collectively make up what is termed the 
class I MHC antigen loading complex. The antigen loading complex members 
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have not been shown to interact with HC after antigen is loaded into the class I 
MHC molecule. Since ERAP1 is in the ER and mediates the final processing step 
of the antigen before loading onto class I MHC, it is reasonable to predict that 
ERAP1 retention in the ER can be through interactions with a component of the 
antigen loading complex though it has not been shown. 
 
The ER Aminopeptidase, ERAP1 
 The ER aminopeptidase, ERAP1, is a 941 residue long aminopeptidase in 
the M1 family of zinc aminopeptidases (Hattori et al., 1999). ERAP1 has also 
been referred to as type 1 tumor necrosis factor receptor shedding 
aminopeptidase regulator (ARTS-1), adipocyte-derived leucine aminopeptidase 
(ALAP), puromycin-insensitive leucine aminopeptidase (PILS-AP) and ER 
aminopeptidase associated with antigen processing (ERAAP) because of 
ERAP1’s characterization by different research groups (Cui et al., 2002; Hattori 
et al., 1999; Schomburg et al., 2000; Serwold et al., 2002). Knockout studies 
have shown that ERAP1 to be the major antigen processing enzyme in the ER 
and knock down studies show that ERAP1 depletion effects the presentation of 
some epitopes (Chang et al., 2005; York et al., 2006). ERAP1 was shown to 
effect the overall cell surface antigen repertoire but does not affect all antigens, 
or even all class I MHC, in CMV infected cells and in non infected cells 
(Blanchard et al., 2010). Additionally, ERAP1 expression was altered in human 
tumors (Fruci et al., 2008; Kazeto et al., 2003; Mehta et al., 2009; Watanabe et 
14
al., 2003). Studies comparing tumor and non tumor cell lines show that ERAP1 
expression is decreased in melanoma, carcinoma and lymphoma cells (Fruci et 
al., 2008). ERAP1 polymorphisms have been observed to correlate with 
increased risk of ankylosing spondylitis, a chronic inflammatory autoimmune 
disease that highly correlates with the class I MHC allele HLA-B27 (Reveille et 
al., 2010; Schlosstein et al., 1973). 
Pull-down studies have shown that ERAP1 interacts with a homologous 
M1 aminopeptidase, ERAP2 (Saveanu et al., 2005; Tanioka et al., 2003). 
Additionally, ERAP1 and ERAP2 have been shown to cleave the same peptide 
(HIV derived peptide, RSLYNTVATL), and have been shown to have different 
peptide cleavage specificity. ERAP1 prefers hydrophobic residues at the N-
terminus and ERAP2 prefers basic residues at the N-terminus (Hattori et al., 
1999; Tanioka et al., 2003). Aside from being upregulated in the ER by cytokines 
where nascent class I MHC awaits peptide loading, ERAP1 has enzymatic 
characteristics that make it specialized for generating peptide antigen (Saric et 
al., 2002). ERAP1 shows substrate size specificity by cleaving peptides from 9-
16 amino acids long more rapidly than shorter peptides (Chang et al., 2005; Saric 
et al., 2002; York et al., 2002). ERAP1 also has an N- and C- terminal residue 
preference for small hydrophobic residues in addition to an internal preference 
for a positively charged residue around 3 residues from the C-terminus (Chang et 
al., 2005; Evnouchidou et al., 2008). These characteristics make it unique 
compared to other M1 aminopeptidase family members, and particularly suitable 
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for class I MHC antigen processing. Since neither ERAP1 nor ERAP2 has an ER 
retention sequence, it remains a mystery as to how these ER resident 
aminopeptidases stay in the ER. It is possible but not shown that ERAP1 and 
ERAP2 interact with members of the antigen loading complex that stabilize the 
nascent class I MHC before peptide loading. Many questions about ERAP1’s 
mechanisms and activities still remain elusive. How does ERAP1 differ from 
other aminopeptidases that allows it to bind N-extended peptides in the ER and 
cleave the peptide to the appropriate length for MHC binding? Chapter 2 reports 
the crystal structure of ERAP1 in complex with the inhibitor, bestatin, and 
suggests a structural basis for peptide trimming. 
 
M1 Family of Aminopeptidases 
 
The M1 family of aminopeptidases, of which ERAP1 is a member, are zinc 
aminopeptidases with a conserved zinc binding motif HExxHx18E and a 
conserved GXMEN motif. Members of this family play a variety of biological 
roles, including insulin regulation, angiotensin III degradation in blood pressure 
regulation, maternal serum regulation in child birth, as well as peptide cleavage 
for antigen processing (Cui et al., 2002; Hattori et al., 1999; Saric et al., 2002; 
Schomburg et al., 2000; Tsujimoto and Hattori, 2005; York et al., 2002). In some 
organisms, such as A. thaliana and P. falciparum, M1 aminopeptidases are 
targeted as a receptor for pesticides (Azimzadeh et al., 2010; Peer et al., 2009). 
Currently, there are structures of eight M1 family members including ERAP1.  
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The structure of ERAP1 will be presented and discussed in detail in Chapter 2. 
The other M1 aminopeptidases for which structures have been solved are human 
leukotriene hydrolase (LTA4H), cold active aminopeptidase (CoAP) from C. 
psychrerythrea, the tricorn interacting factor f3 (TIFF3) from T. acidophilium, 
aminopeptidase N (ePepN) from E. coli, aminopeptidase M1 (PfaM1) from P. 
falciparum and aminopeptidase M1 from N. meningitidis (Bauvois et al., 2008; Ito 
et al., 2006; Kyrieleis et al., 2005; Nocek et al., 2008; Tholander et al., 2008). All 
the above M1 aminopeptidases exhibit primary sequence homology mostly 
around the catalytic region, which is a thermolysin-like domain, and very little 
homology in the C-terminal region. However, the structures exhibit a homologous 
domain arrangement consisting of an α/β N-terminal domain, a thermolysin-like 
catalytic domain, a helical C-terminal domain and in some cases a small 
(inserted) domain between the catalytic and C-terminal domain (Figure 1.3) 
(Bauvois et al., 2008; Ito et al., 2006; Kyrieleis et al., 2005; Nocek et al., 2008; 
Tholander et al., 2008). Substrate specificity and hints on mechanism have been 
suggested for LTA4H and PepN through mutagenesis, inhibition and 
crystallographic studies (Addlagatta et al., 2006; Jiang et al., 2010; Minami et al., 
1992; Tholander et al., 2008). Homology modeling was used to predict that the 
active site of ERAP1 is located in the thermolysin like domain; however, the 
environment of the rest of the peptide binding domain remained elusive. The 
structure of ERAP1 presented in Chapter 2 suggests a common domain 
arrangement among the M1 family of aminopeptidases and a possible 
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mechanism by which ERAP1 can interact with the peptide substrate via the C-
terminal domain that does not have sequence homology to other M1 family 
members. 
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Figure 1.3. Structure of Representative M1 Aminopeptidase Family Member, 
M1 Alanylaminopeptidase from Malaria. The aminopeptidase is shown in 
ribbon representation and the zinc atom is a grey sphere. The domains are 
colored as follows: N-terminal domain I in blue, catalytic domain II in green, 
inserted domain III in brown, C-terminal domain IV in red. The PDB ID for this 
structure is 3EBG. 
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The Oxytocinase Subfamily M1 Family of Aminopeptidases 
ERAP1, ERAP2, and insulin regulated aminopeptidase (IRAP) make up 
the oxytocinase subfamily of M1 aminopeptidase because of their activity on 
peptide hormones and their homology (Tanioka et al., 2003). Primary sequence 
alignment of the three aminopeptidases is shown in Figure 1.4. ERAP1 and 
ERAP2 are ER residents that have been shown to trim antigenic precursors to 
the appropriate length for class I MHC loading and have different N-terminal 
substrate specificities (Saric et al., 2002; Tanioka et al., 2003; York et al., 2002). 
The third member, IRAP, is a membrane protein that co-localizes with the 
glucose transporter 4 in intracellular vesicles targeted to the cell surface (Ross et 
al., 1996). IRAP have been shown to be involved in class I MHC cross 
presentation pathways in endosomes (Saveanu et al., 2009). IRAP unlike ERAP1 
cleaves SIINFEKL to INFEKL, which is not suitable for class I MHC binding 
(Georgiadou et al., 2010). Since the three oxytocinase subfamily members share 
40-49% identity, a structural comparison among the family members may lead to 
insight into how these aminopeptidases can control their product sizes.  
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ERAP1 -------------------MV--------------------------------------- 
ERAP2 -------------------MFHSSAMVNSHRKP--------------------------- 
IRAP  MEPFTNDRLQLPRNMIENSMFEEEPDVVDLAKEPCLHPLEPDEVEYEPRGSRLLVRGLGE 
                         *                                         
 
ERAP1 --------------------FLPLKWSL------------------------ATMSFLLS 
ERAP2 --------------------MFNIHRGF------------------------YCLTAILP 
IRAP  HEMEEDEEDYESSAKLLGMSFMNRSSGLRNSATGYRQSPDGACSVPSARTMVVCAFVIVV 
                                                                                           
 
ERAP1 SLLALLTVSTPSWCQSTE---AS----------PKRSDGTPFPWNKIRLPEYVIPVHYDL 
ERAP2 QICICSQFSVPSSYHFTEDPGAF----------PVATNGERFPWQELRLPSVVIPLHYDL 
IRAP  AVSVIMVIYLLPRCTFTKE-GCHKKNQSIGLIQPFATNGKLFPWAQIRLPTAVVPLRYEL 
                      *                *    *  ***   ***  * *  * * 
 
ERAP1 LIHANLTTLTFWGTTKVEITASQPTSTIILHSHHLQISRATLRKGAGERLSE--EPLQVL 
ERAP2 FVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKVL 
IRAP  SLHPNLTSMTFRGSVTISVQALQVTWNIILHSTGHNISRVTFMSAVSSQ----EKQAEIL 
        * ***   *             *  *****    *   *                  * 
 
ERAP1 EHPRQEQIALLAPEPLLVGLPYTVVIHYAGNLSETFHGFYKSTYRTKEGELRILASTQFE 
ERAP2 SYPAHEQIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFE 
IRAP  EYAYHGQIAIVAPEALLAGHNYTLKIEYSANISSSYYGFYGFSYTDESNEKKYFAATQFE                                  
            ***   ** *     *               ***   *     *    * * ** 
 
ERAP1 PTAARMAFPCFDEPAFKASFSIKIRREPRHLAISNMPLVKSVTVAEGLIEDHFDVTVKMS 
ERAP2 PTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDHFETTVKMS 
IRAP  PLAARSAFPCFDEPAFKATFIIKIIRDEQYTALSNMPKKSSVVLDDGLVQDEFSESVKMS 
      *  ** ******** *** * *** *     * ****         **  * *   **** 
 
ERAP1 TYLVAFIISDFESVSKITKSGVKVSVYAVPDKINQADYALDAAVTLLEFYEDYFSIPYPL 
ERAP2 TYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFDIYYPL 
IRAP  TYLVAFIVGEMKNLSQDVN-GTLVSIYAVPEKIGQVHYALETTVKLLEFFQNYFEIQYPL 
      ***** *       *     *  ** ** * *  *  ***     ** *   ** * *** 
 
ERAP1 PKQDLAAIPDFQSGAMENWGLTTYRESALLFDAEKSSASSKLGITMTVAHELAHQWFGNL 
ERAP2 SKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNL 
IRAP  KKLDLVAIPDFEAGAMENWGLLTFREETLLYDSNTSSMADRKLVTKIIAHELAHQWFGNL 
       * ** *****  ******** * **  ** *   **       *   ************ 
 
ERAP1 VTMEWWNDLWLNEGFAKFMEFVSVSVTHPELKVGDYFFGKCFDAMEVDALNSSHPVSTPV 
ERAP2 VTMEWWNDIWLNEGFAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPA 
IRAP  VTMKWWNDLWLNEGFATFMEYFSLEKIFKELSSYEDFLDARFKTMKKDSLNSSHPISSSV 
      *** **** *******  **         **     *    *     * **** * *    
 
ERAP1 ENPAQIREMFDDVSYDKGACILNMLREYLSADAFKSGIVQYLQKHSYKNTKNEDLWDSMA 
ERAP2 ETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLS 
IRAP  QSSEQIEEMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHNHSYASIQSDDLWDSFN 
          ** ****  ** **   * **   *    *      **   **      *** *   
 
ERAP1 SIC-PTDGVKGMDGFC-SRSQHSSSSSHWHQEGVDVKTMMNTWTLQKGFPLITITVRGRN 
ERAP2 NSCLESDFTSG--GVCHSDPKMTSNMLAFLGENAEVKEMMTTWTLQKGIPLLVVKQDGCS 
IRAP  EVT---------------------------NQTLDVKRMMKTWTLQKGFPLVTVQKKGKE 
                                         ** ** ******* **         
 
ERAP1 VHMKQEHYMKG------SDGAPDTGYLWHVPLTFITSKSDMVHRF---LLKTKTDVLILP 
ERAP2 LRLQQERFLQGVFQEDPEWRALQERYLWHIPLTYSTSSSNVIHRH---ILKSKTDTLDLP 
IRAP  LFIQQERFFLNM---KPEIQPSDTSYLWHIPLSYVTEGRNYSKYQSVSLLDKKSGVINLT 
          **                   **** **   *             *  *     *  
 
ERAP1 EEVEWIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIGKL 
ERAP2 EKTSWVKFNVDSNGYYIVHYEGHGWDQLITQLNQNHTLLRPKDRVGLIHDVFQLVGAGRL 
IRAP  EEVLWVKVNINMNGYYIVHYADDDWEALIHQLKINPYVLSDKDRANLINNIFELAGLGKV 
      *   * * *   ********    *  *   *          **  **   * *   *   
 
ERAP1 SIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRLLRDLID 
ERAP2 TLDKALDMTYYLQHETSSPALLEGLSYLESFYHMMDRRNISDISENLKRYLLQYFKPVID 
IRAP  PLKRAFDLINYLGNENHTAPITEALFQTDLIYNLLEKLGYMDLASRLVTRVFKLLQNQIQ 
          * *   **  *         *      *                          *  
 
ERAP1 KQTWTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESNGNLSLPVDVTLAVF 
ERAP2 RQSWSDKGSVWDRMLRSALLKLACDLNHAPCIQKAAELFSQWMESSGKLNIPTDVLKIVY 
IRAP  QQTWTDEGTPSMRELRSALLEFACTHNLGNCSTTAMKLFDDWMASNGTQSLPTDVMTTVF 
       * * * *    * *** **  **      *   *   *  *  * *    * **   *  
 
ERAP1 AVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEF 
ERAP2 SVGAQTTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNL 
IRAP  KVGAKTDKGWSFLLGKYISIGSEAEKNKILEALASSEDVRKLYWLMKSSLNGDNFRTQKL 
        ***    **  *   *    *  *   *  **       **  *      *    **   
 
ERAP1 PQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFELGSSSIAHMVMGTTNQFSTRTRLEEVK 
ERAP2 AALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYDIRMIISGTTAHFSSKDKLQEVK 
IRAP  SFIIRTVGRHFPGHLLAWDFVKENWNKLVQKFPLGSYTIQNIVAGSTYLFSTKTHLSEVQ 
              *   *  *** *   **  *  ** ***  *     * *  **    * **  
 
ERAP1 GFFSSLKENGSQLRCVQQTIETIEENIGWMDKNFDKIRVWLQSEKLEHDPEADATG 
ERAP2 LFFESLEAQGSHLDIFQTVLETITKNIKWLEKNLPTLRTWLMVNT----------- 
IRAP  AFFENQSEATFRLRCVQEALEVIQLNIQWMEKNLKSLTWWL--------------- 
       **         *   *   * *  ** *  **      ** 
Figure 1.4. Sequence Alignment of Human ERAP1, ERAP2, and IRAP 
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 Structural Features of Class II MHC 
 
Class II MHC molecules present self and foreign peptide antigens to CD4+ 
T cells. Class II MHC molecules are heterodimers consisting of two subunits, the 
α chain and the β chain. Each chain has an upper domain that contributes to the 
peptide binding groove, a membrane-proximal IgG-like domain, a 
transmembrane domain, and a cytoplasmic tail (Bjorkman et al., 1987; Stern et 
al., 1994). Peptide elution studies suggest that the average-sized peptide  bound 
to a class II MHC is about 13-20 residues in length, which is longer than peptides 
that bind to class I MHC (Chicz et al., 1992; Rudensky et al., 1991). The class II 
MHC peptide binding domain is made of both the α and β chain, each 
contributing one helix lining the groove and half of the beta sheet that makes up 
the “floor” of the binding groove (Figure 1.4). Crystal structures show that 
conserved interactions between the main chain of the bound peptide and main 
chain and side chains of the MHC hold the peptide in a polyproline type II 
conformation independent of the peptide sequence (Figure 1.5) (Stern et al., 
1994). The amino and carboxyl-termini of peptides bound to class II MHC are 
free to extend beyond the boundaries of the peptide binding groove (Stern et al., 
1994). Although main chain interactions hold the peptide in the groove, peptide 
side chain sequence specificity still exists, and is dictated by pockets lining the 
peptide binding groove (Figure 1.6) (Stern et al., 1994; Zavala-Ruiz et al., 2004a; 
Zavala-Ruiz et al., 2003).  The binding specificity of the class II MHC, HLA-DR1, 
has been well studied, and is usually discussed as a nine amino acid binding 
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“register” (P1-P9). HLA-DR1 has a P1 binding pocket that can accommodate 
large hydrophobic residue. Binding studies have shown that the P1 position plays 
a major role in dictating whether a peptide will bind to the class II MHC molecule 
(Jardetzky et al., 1990). Other pockets on the MHC also contribute to peptide 
binding specificity. For HLA-DR1, the P4 pocket prefers aliphatic amino acids; 
the P6 pocket is more of a shelf that prefers small amino acids; P9 prefers 
aliphatic residues; and P10 (outside the canonical “register”) shows a preference 
for phenylalanine or tyrosine (Jardetzky et al., 1990; Stern et al., 1994; Zavala-
Ruiz et al., 2004a; Zavala-Ruiz et al., 2003). The crystal structure of HLA-DR1 
with the T cell receptor, HA1.7, specific for HLA-DR1 bound to the flu 
hemagglutinin-derived peptide, HA, (PKYVKQNTLKLAT) shows that the italicized 
residues to be anchored into pockets in the MHC and the underlined residues 
protrude out of the peptide binding groove and act as T cell contacts that were 
shown to be important in T cell activation studies (Hennecke and Wiley, 2002).  
Prediction programs such as RANKPEP and SYFPEITHI can take a long peptide 
sequence and suggest a binding motif in the peptide binding register of the MHC 
and suggest residues that may interact with the T cell receptor (DiBrino et al., 
1994; Rammensee et al., 1999; Reche et al., 2004). However, the information 
about flanking residues outside the peptide binding pockets is limited and 
Chapter 4 will discuss studies of an HIV derived peptide that exhibits a C-
terminal hairpin loop that is important for T cell activation.  
24
 
25
 
Figure 1.5. Class I and Class II MHC Main Chain with Peptide Interactions. 
MHC molecules are represented in ribbon diagram. Top panel shows a class I 
MHC molecule heavy chain is green. Both termini of the peptide interact with the 
MHC molecule. Bottom panel shows a class II MHC molecule. The α chain is 
green and the β chain is cyan. The termini of the peptide extends outside the 
groove. The hydrogen bonding network holds the peptide in a polyproline type II 
conformation. Peptides in both molecules are represented in yellow sticks 
representation. Hydrogen bonding interactions are represented in dotted lines. 
The same PDB ID is in Figure 1.2. 
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Figure 1.6. Peptide Binding Pockets in Class I and Class II MHC. The surface 
of MHC molecules is shown here is brown and peptides are represented as 
yellow sticks. Peptide labeling is coordinated with its binding pocket in the MHC. 
Top panel shows class I MHC, H2-Kb, having large pockets at P5 and P8 that 
explains the preference for binding to large hydrophobic groups in those 
positions. Bottom panel show the class II MHC, HLA-DR1, having pockets at P1, 
P4, P6, and P9 that can allow for binding specificities. Same PDB ID is in Figure 
1.2. 
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Class II MHC Antigen Processing Pathway 
Peptide sources for class II MHC typically are proteins that are 
endocytosed into endosomes, where they are degraded into small peptide 
fragments and loaded onto class II MHC molecules. The α and β chains of class 
II MHC molecules are synthesized in the ER where the peptide binding groove is 
occupied by a chaperone called the invariant chain (Lamb and Cresswell, 1992; 
Roche and Cresswell, 1990). The class II MHC/invariant chain complex then 
traffics into endosomes where cleaved peptide fragments await. The lowered pH 
in the endosomal compartments activates proteases that cleave long versions of 
the invariant chain, leaving a shorter peptide fragment called “CLIP” in the 
peptide-binding groove (Lamb and Cresswell, 1992; Riberdy et al., 1992). 
Between the early endosome and late endosome, the peptide antigen replaces 
CLIP in the peptide-binding groove of the MHC. Class II MHC-like molecules, 
HLA-DM and HLA-DO, play a role in loading of peptides into MHC (Kropshofer et 
al., 1998; van Lith et al., 2001).  HLA-DM has been termed the “peptide editor” 
because it facilitates the exchange of peptides in the groove including release of 
CLIP, and may affect the suitability of peptides that are eventually bound and 
presented at the cell surface (Denzin and Cresswell, 1995; Kropshofer et al., 
1998; Sherman et al., 1995).  HLA-DO can modulate HLA-DM and has inhibitory 
functions in peptide loading. HLA-DM is active between neutral and slightly acidic 
pH but optimal at pH 5.5. However, HLA-DO does not affect HLA-DM activity at 
acidic pH (Alfonso et al., 1999; Liljedahl et al., 1998). The molecular mechanisms 
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of peptide loading/exchange and the interactions between HLA-DM and HLA-DO 
with class II MHC remain unclear. The balance of the activities of HLA-DM, HLA-
DO, and other facets of the endosomal environment result in the final array of 
class II MHC peptide complexes presented on the cell surface for CD4+ T cell 
recognition. Chapter 3 describes characterization of an environmentally sensitive 
fluorogenic peptide that can be utilized for real time visualization of the peptide 
loading process.  
 
MHC/Peptide and TCR Modes of Interaction 
While there is much diversity in alleles of class I and class II MHC, there is 
significantly more diversity in T cell receptors (TCRs). TCRs exhibit similar 
structures to antibodies including two IgG-like constant domains (Cα and Cβ) and 
two IgG-like variable domains (Vα and Vβ) (Reinherz et al., 1999). The variable 
domains consist of complementarity-determining regions are made of loops 
(CDR loops) with extreme variability, and these loops that interact with the MHC-
peptide complex (Hennecke and Wiley, 2002). While TCRs are selected during 
development are “restricted” by an MHC allele, the receptor will still not be 
activated unless an appropriate antigenic peptide is presented. Binding studies 
suggested that the interactions between the TCR and MHC follow a two step 
mechanism, where first the TCR interacts with regions of the MHC, which then 
interact with the peptide in the groove (Wu et al., 2002). Currently there are 
twelve structures of α/β TCRs bound to MHC peptide complexes. The 
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interactions between the TCR and MHC peptide complex can be described as 
having a diagonal or non-diagonal mode of interaction. In the diagonal mode of 
interaction is when the TCR interact with the MHC α1 helix near the peptide N-
terminus and diagonally across the peptide binding groove towards the peptide 
C-terminus and interact the MHC β1 helix. TCR interaction is over the center of 
the peptide (Figure 1.5) (Hennecke and Wiley, 2002). The non-diagonal mode of 
interaction is exhibited when the TCR is tilted and causes a biased towards the 
N-terminus of the peptide as observed in TCR Ob.1A12-HLA-DR2-mylin basic 
protein derived peptide (Maynard et al., 2005). The observed non-diagonal TCR/ 
MHC structures were of complexes consisting autoreactive TCR and self peptide 
MHC peptide complexes (Deng et al., 2007; Hahn et al., 2005; Maynard et al., 
2005). These structures suggest that the MHC and TCR interactions are weak 
and allow for escape of TCR negative selection where the stronger self TCR are 
selected out (Rudolph et al., 2006).  These different modes of interactions show 
that the MHC/TCR binding orientation is not strictly conserved (Figure 1.7). 
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Figure 1.7. Modes of Interaction Between α/β TCR and Class II MHC. The 
molecules are represented in ribbon where the MHC α chain is green and β 
chain is cyan. The TCR α chain is yellow and β chain is pink. The peptide is 
magenta. The top panel shows the HA.17 TCR with the class II MHC, HLA-DR1, 
bound to HA peptide (PDB 1FYT). This complex structure exhibits a diagonal 
interaction between the MHC and TCR. The TCR interactions start from the α1 
helix and diagonally across the peptide binding groove to β1 helix of the MHC 
and the TCR interaction is over the center of the peptide. The bottom panel 
shows the Ob.1A12 TCR with the class II MHC, HLA-DR2, bound a self peptide 
derived from myelin basic protein, MBP peptide (PDB 1YMM). This exhibits a 
non-diagonal interaction between the MHC and TCR. The TCR interacts less 
with the center of the peptide but instead the N-terminal part of the peptide and 
MHC β chain. 
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Whether other and more different TCR and peptide MHC interaction 
orientations occur remains to be seen. T cell lines grown from HIV patients that 
respond specifically to a C-extended gag envelope-derived peptide, GagP16 
(PEVIPMFSALSEGATP), but not the shorter version of the same peptide, 
GagP13 (PEVIPMFSALSEG), suggest a possibility of another mode of TCR and 
peptide MHC interaction biased toward residues extending beyond the C-
terminus of the peptide-binding register of class II MHC (Figure 1.8) (Norris et al., 
2006; Zavala-Ruiz et al., 2004b). Structural studies of HLA-DR1 bound to the 
GagP16 and HLA-DR1 bound to GagP13 shows that both peptides bind into the 
HLA-DR1 peptide binding groove in the same register with an exception of a 
hairpin-like loop in the C-terminus of the GagP16 peptide composed of the last 
five residues (EGATP) where the proline loops back towards the glutamate 
(Zavala-Ruiz et al., 2004b). Predicted T cell and peptide interactions are present 
in both gag envelope-derived peptides (Zavala-Ruiz et al., 2004b). Future studies 
of co-crystal structures of this TCR with the two peptide-MHC complexes will 
show whether the docking orientation in this system is different in a way that is 
biased towards the C-terminus of the peptide. In Chapter 4, structural studies will 
be discussed about the determinants of the C-terminal hairpin loop that are 
important for T cell activation. 
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Figure 1.8. HIV Gag Derived Peptides in Class II MHC.  The structures of the 
two gag derived peptides, GagP13 and GagP16, were overlay in the peptide 
binding groove of HLA-DR1 shown in grey ribbon and surface. The surface of the 
MHC molecule is transparent gray to allow visualization of peptide side chains 
inside the binding groove. This illustrates that GagP13 and GagP16 binds in the 
MHC molecule identically and the major difference between the two peptides in 
the context of HLA-DR1 is that the C-terminal hairpin loop exhibited only by 
GagP16 can activate AC25 TCR expressing T cells. The PDB IDs used in this 
figure are 1SJE and 1SJH. 
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Studies in This Thesis 
 The work in this thesis will contribute to understanding class I and class II 
antigen processing and class II MHC interaction with αβ TCR. In class I antigen 
presentation, the structural studies of ERAP1 will allow an understanding of how 
ERAP1 can exhibit unusual aminopeptidase specificity compared to other 
members of the M1 family of aminopeptidases, allowing ERAP1 to perform 
antigen processing activity. In class II antigen processing, structural 
characterization of an environmentally sensitive peptide probe bound to HLA-
DR1 allowed for peptide binding studies in vivo to further understand endosomal 
antigen processing. To study class II MHC interaction with αβ TCR, HLA-DR1 
bond to a series of gag-derived peptides were structurally characterized to 
investigate the role of the hairpin loop in class II MHC interaction for αβ TCR. 
These studies are meant to increase our understanding of the peptidases and 
presenting molecules that are involved in antigen peptide presentation for T cell 
recognition. 
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CHAPTER 2 
Structural Basis For Antigenic Peptide Precursor Trimming By ERAP1, The 
Endoplasmic Reticulum Aminopeptidase Involved In Antigen Processing 
 
The work presented in this chapter is in collaboration with the laboratories 
of Alfred Goldberg and Efstratios Stratikos. I did the crystallographic work, the 
Goldberg laboratory did the biochemistry experiments showing that short 
peptides are activators of small fluorogenic substrates and the Stratikos 
laboratory executed the normal mode analysis and enzymatic experiments with 
peptide substrates.  
 
INTRODUCTION  
Most major histocompatibility complex (MHC) class I proteins have strict 
requirements on the lengths of peptide ligands that can be bound with high 
affinity, typically 8-10 residues, and therefore peptides destined for presentation 
by class I MHC molecules must be precisely cleaved before loading (Rock et al., 
2004).  Proteasomal degradation and cytosolic aminopeptidase processing are 
sufficient for the generation of some class I MHC antigens, but a majority of 
epitopes require an additional processing step in the endoplasmic reticulum (ER) 
after TAP-mediated transport (Fruci et al., 2001; Serwold et al., 2001). A search 
for the peptidase(s) responsible for that activity identified an ER-resident, 
interferon-γ inducible, metalloaminopeptidase that was termed ERAP1 (ER-
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associated aminopeptidase 1) or ERAAP (ER aminopeptidase associated with 
antigen processing) (Saric et al., 2002; Serwold et al., 2002).  
 ERAP1 processing impacts a large number of self and foreign epitopes.  
Studies of ERAP1-deficient cells have shown that ERAP1 generates many 
presented peptide epitopes from larger precursors, but it can destroy other 
epitopes by trimming them below the minimal size needed for MHC class I 
binding (York et al., 2002).  The peptide repertoire carried by MHC molecules of 
wild-type and ERAP1–deficient mice differ substantially (Blanchard et al., 2010; 
Hammer et al., 2007). Epitope immunodominance hierarchies differ in wild-type 
and ERAP1–deficient mice infected with LCMV (York et al., 2006), and T cell 
responses against many model antigens were reduced in ERAP1 deficient mice 
(Yan et al., 2006). Furthermore, cross-presentation of cell-associated epitopes 
was lower in ERAP1-deficient mice (Firat et al., 2007).  ERAP1-dependent 
epitopes were shown to be important in resistance to Toxoplasma gondii 
(Blanchard et al., 2008).  
 Allelic variants of ERAP1 have been linked to a number of human 
diseases, including the autoimmune disease ankylosing spondylitis (AS) 
(reviewed in (Brown, 2010)), diabetes (Fung et al., 2009), some forms of cervical 
cancer (Mehta et al., 2009), and high blood pressure  (Yamamoto et al., 2002). 
 An important aspect of ERAP1’s specificity related to its biological function 
is its ability to cleave long substrates, in contrast to other aminopeptidases, which 
generally are restricted to substrates shorter than 4 residues (Chang et al., 
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2005). ERAP1’s length specificity is characterized by a sharp increase in activity 
near 8-10 residues, with peptides up to ~16 residues being processed efficiently 
(Chang et al., 2005; York et al., 2002).  This activity matches ERAP1’s role in 
processing antigenic peptide precursors.  Cytosolic proteasomal processing 
generates peptides of 2-25 residues (Kisselev et al., 1999) with C-terminal 
residues that generally match MHC class I sequence requirements, and 
TAP1/TAP2, the transporter associated with antigen processing that brings 
antigen precursors into the ER, prefers of peptides 8-16 residues long (Momburg 
et al., 1994). Therefore, many transported peptides require additional trimming to 
fit into MHC class I binding sites, which typically are restricted to binding peptides 
that are 8-10 residues long (Rammensee, 1995). Post-proteasomal processing 
by ER aminopeptidases can be considered to be the final contributor to size 
selection of antigenic peptides.  How ERAP1 plays this role is controversial; in 
addition to ERAP1’s intrinsic length dependence (Chang et al., 2005). Peptide 
hydrolysis in the presence and absence of class I MHC suggest that direct 
processing of antigenic precursors by ERAP1 while partially bound to MHC class 
I because MHC can protect peptides from being further cleaved by ERAP1 (Falk 
et al., 1990; Kanaseki et al., 2006). MHC-protection and peptide products 
released from ERAP1 can also contribute to the final repertoire of peptides 
loaded onto class I MHC.   
 ERAP1 has sequence as well as length specificity.  ERAP1 was originally 
identified as a leucine-specific aminopeptidase based on studies with single 
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amino acid fluorogenic substrates (Hattori et al., 1999). The activity of ERAP1 
towards peptides with various N-terminal residues has been characterized in 
detail in vitro.  The N-terminal sequence specificity observed for peptides 
generally parallels findings from single residue model substrates, although with 
substantially broader overall reactivity, so that some N-terminal residues are 
processed efficiently in the context of longer peptides but not as single residue 
substrates (Chang et al., 2005; Evnouchidou et al., 2008; Hearn et al., 2009; 
Saveanu et al., 2005; Serwold et al., 2001).  An in vivo study of ERAP1-mediated 
generation of T cell epitopes from longer antigenic precursors reported that the 
N-terminal specificity matches the enzyme’s peptide specificity measured in vitro  
(Hearn et al., 2009). A statistical analysis of residues preceding naturally 
processed epitopes in large epitope databases also concurred (Hearn et al., 
2009).  Finally, in addition to its N-terminal specificity, ERAP1 is unusual in 
exhibiting specificity for the substrate’s C-terminal residue (Chang et al., 2005) 
and internal sequence (Evnouchidou et al., 2008). 
 To clarify the structural basis for ERAP1 specificity and to evaluate 
possible models for its length dependence, we determined the 3.0 Å crystal 
structure of ERAP1 bound to the aminopeptidase inhibitor bestatin by X-ray 
diffraction. The structure reveals an open conformation with a large interior 
compartment. A shallow groove extending from the active site potentially can 
accommodate long peptides forming a series of electrostatic and hydrophobic 
interactions consistent with previously reported substrate preferences. 
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Experimental characterization of ERAP1’s sensitivity to allosteric activation and 
inhibition by peptides, and comparison with the active site geometries of other 
M1 family members suggest a mechanism for the length-dependent hydrolytic 
activity and allows us to propose a molecular model of how ERAP1 trims 
antigenic peptide precursors.  
 
MATERIALS AND METHODS 
 
Protein expression and purification  
Human recombinant ERAP1 was expressed using a baculovirus insect 
cell expression system as previously described (Evnouchidou et al., 2008). We 
used an ERAP1 allelic variant with four substitutions (G346D, G514D, K528R, 
Q730E) relative to the GenBank reference sequence NP_057526. ERAP1 was 
purified using Ni-NTA resin (Qiagen), eluted with 100 mM imidazole pH 8.0, 
concentrated to 1 mg/mL by centrifugal ultrafitration and treated with 
carboxypeptidase A (Sigma) (molar ratio 5:1) at room temperature in PBS with 
0.25 mg/mL protein disulfide isomerase, PDI (Sigma). Carboxypeptidase A was 
removed with size exclusion chromatography (S200 column, GE Healthcare), 
and finally ERAP1 was purified by anion exchange chromatography (MonoQ, GE 
Healthcare).   A single band was observed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis.  Enzyme specific activity was monitored 
using L-AMC hydrolysis, and the specific activity increased as the protein was 
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purified.  
 
 
Crystallization and data collection   
ERAP1-bestatin complexes were crystallized by vapor diffusion in hanging 
drops after extended storage at 4°C.  The crystallization reservoir solution 
consisted of 14% PEG 8000, 1 mM glutathione (10:1 ratio oxidized to reduced), 
0.1 M Bicine, pH 8.6. The drops consisted of equal volumes reservoir and the 
protein solution (6.5 mg/mL ERAP1, 5:1 molar ratio bestatin, 0.25 mg/mL PDI). 
Crystals were transferred to reservoir solution containing 30% 2-methyl-2,4-
pentanediol and flash frozen in liquid nitrogen. X-ray diffraction data were 
collected as 1° oscillations at 100 K with 1.08 Å radiation at beamline X29A in the 
National Synchrotron Light Source. Data were processed and scaled using 
HKL2000 (Otwinowski, 1997). Data collection and refinement statistics are 
shown in Table 2.1. 
 
Structure determination and refinement 
 Phases were estimated by molecular replacement using PHASER (McCoy 
et al., 2007) with LTA4H (PDB 1HS6) and TIFF3 (PBD 1Z5H) as search models. 
A solution with three molecules, as suggested by Matthews coefficient analysis, 
was obtained yielding electron density of sufficient quality for model building. To 
validate the molecular replacement solution, composite omit maps (CNS) 
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(Brunger, 2007) were generated and inspected using COOT (Emsley and 
Cowtan, 2004) and O (Jones et al., 1991). Phases were improved in RESOLVE 
(Terwilliger, 2000) with 3-fold non-crystallographic symmetry real-space 
averaging. Averaged and unaveraged omit and prime-and-switch maps 
(Terwilliger, 2000) were utilized for model building. The entire C-terminal domain 
was different from the search models and was built de novo, whereas the N-
terminal domains could be modeled based on the search models. Positions of 
three N-linked glycosylation sites (Asn 70, 154 and 760), and two disulfide bonds 
(410-449 and 742-749) matched sites of these modifications as observed by 
mass spectrometry (data not shown). After a complete monomer model was built, 
a trimer was reconstructed and inspected. Electron density consistent with a five 
monosaccharide unit chain [Man(a1->6),Man(a 1->3)]-Man(b1->4)->GlcNAc(b1-
>4)->GlcNAc(1-4)-Asn] was observed linked to Asn 70 in two of the three 
molecules in the asymmetric unit, with a disaccharide unit at the other. At the two 
other glycosylation sites, no electron density or density consistent with only a 
monosaccharide was observed. Crystallographic rigid body, positional, B-factor, 
and TLS refinement was performed in PHENIX (Adams et al., 2010) with NCS 
restraints between each of the four domains of the trimer. The NCS restraints 
were optimized to be higher in domain II and lower in domains I, III, and IV. 
Geometric parameters for bestatin were obtained from the HIC-UP server 
(Kleywegt and Jones, 1998) During cycles of model building and refinement, the 
high resolution limit was increased.  The inclusion of high resolution data shells 
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improved electron density maps, cross-validation statistics, and allowed building 
of some regions, despite having low I/σI and high Rsym values.  
 The completed model consists of ERAP1 residue 46 to residue 934 (of 
941 encoded by the expression vector) with five unobservable loops, between 
residues 416 to 434, 485 to 514, 551 to 556, 863 to 868 and 892 to 904. The 
second and longest corresponds to an ERAP1-specific insertion not required for 
enzymatic activity (ES, unpublished data); the others are exposed loops. 
Ramachandran statistics showed all residues in the allowed regions. Diffraction 
data and coordinates were deposited into the Protein Data Bank (PDB 3MDJ).  
 
RESULTS 
 
Overall Structure of ERAP1 
 ERAP1 is a member of the M1-family of zinc metallopeptidases 
characterized by GAMEN and HExxHx18E sequence motifs. The family includes 
a wide variety of soluble and membrane-associated aminopeptidases with 
various specificities and biological functions (Rawlings et al., 2009). Sequences 
of the five M1-family aminopeptidases for which crystal structures have been 
determined are aligned in Figure 2.1: human leukotriene A4 hydrolase (LTA4H), 
T. acidophilium tricorn interacting factor F3 (TIFF3), E. coli aminopeptidase N 
(ePepN), P. falciparum aminopeptidase M1 (PfAM1), and C. psychrerythraea 
cold active aminopeptidase (ColAP).   These structures reveal increasingly 
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extensive elaborations of a thermolysin-like fold.  Sequence homology is 
strongest in the catalytic domain containing the conserved GAMEN and 
HExxHx18E motifs, weaker in the N-terminal portion, and essentially absent in the 
highly variable C-terminal helical region (Figure 2.1). 
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Figure 2.1. Structure Based Alignment M1 Aminopeptidase Family 
Members. Numbering corresponds to ERAP1, colored lines indicate domains in 
ERAP1; arrows and coils represent strands and helices, respectively, and 
dashes represent loops not observed in crystal structure. Highlighted residues 
are homologous among the aminopeptidases shown and boxed residues are 
highly conserved M1 aminopeptidase motifs HExxEx18E, GAMEN and Tyr438. 
Disulfide bonds are shown by connected bars and observed glycosylation sites 
are indicated by balloon icons. Figures were generated using 3D-COFFEE 
(Notredame et al., 2000). 
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 The crystal structure of full-length recombinant human ERAP1 bound to 
the aminopeptidase inhibitor bestatin was determined by X-ray crystallography 
using cryogenic diffraction data extending to 3.0 Å (Table 2.1).  The structure 
was solved by molecular replacement using LTA4H and TIFF3 as search 
models, with initial phasing using non-crystallographic symmetry relationships 
among the three copies of ERAP1 observed in the crystallographic asymmetric 
unit  (Figure 2.2). Electron density was sufficient for model building of C-terminal 
domain de novo. Figure 2.3 shows an example of electron density from data 
collected. The interactions between the three molecules might provide a model 
for observed ERAP1 interaction with ERAP2 in pull down experiments (Saveanu 
et al., 2005). 
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Table 2.1. Data Collection and Refinement Statistics for ERAP1 
 
. 
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Figure 2.2. ERAP1 Trimer in the Crystallographic Asymmetric Unit.    
Ribbon representation of an asymmetric unit shows the trimeric arrangement of 
the crystallographically distinct molecules. ERAP1 main chain is represented in 
ribbon, the zinc atoms are shown as black spheres, and N-linked sugars and 
bestatin are shown in stick representation. 
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Figure 2.3. Electron Density for ERAP1.  Top. Omit map shows portions of 
helices 10, 12, and 14 in domain IV. All atoms shown (residues 590:780) were 
omitted from model calculations.   Bottom. Omit map showing Tyr438 on helix 5, 
helix 3, helix 4 in domain II and a loop from domain III.  All atoms shown were 
omitted from map calculation.  Blue mesh represents  |2Fo-Fc| electron density, 
lines represent ERAP1 model. 
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The crystal structure of ERAP1 reveals four protein domains, with a large 
cavity between domains II and IV (Figure 2.4).  As with other M1-family 
members, domain II (green in Figure 2.4) is the catalytic domain that carries the 
zinc atom, GAMEN, and HExxHx18E motifs on a thermolysin-like αβ fold. Domain 
I (blue) is an all-β sandwich domain that docks on top of the thermolysin domain, 
capping off the active site and providing binding sites for the amino terminus of a 
substrate peptide. Domain III (orange) is a small β-sandwich domain between 
domains II and IV. Among M1-family aminopeptidases, domain IV (red) is the 
most variable, ranging from a tightly closed spiral of ten helices in LTA4H to 
seventeen helices in ePepN.  In ERAP1, domain IV is composed of sixteen 
variously sized helices arranged as eight antiparallel Armadillo/HEAT-type helix-
turn-helix repeats (Andrade et al., 2001) assembled side-to-side to form a 
concave surface facing toward the active site (Figure 2.5). Overall, the helices of 
the C-terminal helical domain are arranged in a large cone or bowl adjacent to 
the active site, lined by the lateral faces of the even-numbered helices.  
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Figure 2.4. Structure of ERAP1. Overall shape of ERAP1 represented as a 
ribbon diagram and colored according to domains: blue is domain I, green is 
domain III, orange is the domain III, and red is domain IV. Dotted lines represent 
disordered loops. Zinc is represented as a black sphere. 
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Figure 2.5. Schematic Diagram of the C-terminal Domain of ERAP1. Helices 
are represented as cylinders showing the ARM/HEAT motif spiral forming a large 
cavity lined by even numbered helices. 
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A striking feature of the structure is the formation of a deep cavity between 
domains II and IV. This cavity is the largest seen to date for an aminopeptidase 
and potentially can provide easy access to the catalytic site for even the longest 
of the enzyme’s substrates. Figure 2.6 shows views of the cavity, in which most 
of domain I has been removed to allow better visualization of the extent of the 
cavity.  Dimensions of the cavity are shown. This cavity, which extends up to 36 
Å from the active site to the interior surface of domain IV, is likely to represent a 
binding site for long peptide substrates.  
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Figure 2.6. Large Cavity Formed by the Catalytic Domain II and C-terminal 
Domain IV. The cavity is shown in a surface representation. Inset shows how the 
N-terminal domain was removed above the dashed black line to provide a clear 
view of the cavity.  Blue dashed lines represent estimated distances across the 
cavity. 
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Catalytic Site 
 The ERAP1 active site is formed at the junction of five secondary structure 
elements:  helix 2 and the adjacent antiparallel helix 3 that carry the HExxH and 
E residues of the HExxHx18E motif, the GAMEN loop, the domain 1 loop, and 
helix 5 adjacent to the domain II-domain IV interface (Figure 2.7). Bestatin, an α−
hydroxy β-amino dipeptide analog that functions as a broad spectrum 
aminopeptidase inhibitor, binds to the active site of ERAP1 via a bidentate 
interaction between its 2-hydroxy and amido oxygen atoms and the ERAP1 
catalytic zinc atom. The catalytic zinc atom is coordinated by the side chains of 
His353 and His357 of the HExxH helix and Glu376 of the adjacent helix, with 
Glu354 next to bestatin’s α-hydroxyl group (Figure 2.8).  The bestatin amino 
terminus is bound by Glu183 of the domain 1 loop and Glu320 of the GAMEN 
motif.  These interactions are likely to simulate the complex of ERAP1, substrate 
amide, and water molecule positioned to attack the peptide’s scissile bond.  In 
addition, the main chain of GAMEN residues Gly317 and Ala318 interact with 
bestatin’s carboxylate and amide bond, respectively.  The Met319 side chain 
forms part of the S1 pocket, and the Glu320 side chain carboxylate interacts with 
bestatin’s free amino terminus (Figure 2.8).  Asn321, the last of the GAMEN 
residues, forms hydrogen bonds with the neighboring strand that appear to 
stabilize the local loop conformation (not shown). These interactions are likely to 
simulate the interaction of ERAP1 with the first few residues of a bound peptide 
substrate.  The last component of the active site is Tyr438 on the interfacial helix.  
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This tyrosine is conserved in all M1 family aminopeptidases (Rawlings et al., 
2009), and has been shown to play an important catalytic role in stabilizing the 
tetrahedral intermediate formed by water addition to the substrate scissile 
peptide bond (Thompson et al., 2006).  In the ERAP1-bestatin complex, Tyr438 
is positioned near the active site but is oriented such that its hydroxyl group is 
more than 8 Å away from bestatin’s amide bond, where it cannot participate in 
catalysis (Figure 2.8).  
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Figure 2.7. The Active Site of ERAP1. Structural elements forming the ERAP1 
active site.  Bestatin is shown with cyan bonds, zinc as a black sphere, and 
nearby ERAP1 loops, and helices shown as cylinders, are colored as in Figure 
2.2.   ERAP1 residues in the active site are shown with white bonds.  Inset at 
right shows the entire protein for orientation; in the view shown in panel where 
helices 19 and 21 that occlude the active site were removed for clarity. 
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Figure 2.8. The Inhibitor Inside ERAP1 Active Site. ERAP1 interactions with 
bound aminopeptidase inhibitor, bestatin. Side chains of conserved catalytic 
residues of ERAP1 are shown in with bonds colored by domain. Residues from 
domain I are represented in blue and residues from domain II are in green. 
Yellow arc indicates S1 site. 
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 Structural alignment of the active sites of M1 aminopeptidases reveals 
constellations of conserved catalytic residues that are essentially identical to 
those of ERAP1, with the exception of Tyr438 (Figure 2.9).  In all the other M1 
structures but one (TIFF3), the analog of Tyr438 is oriented toward the active 
site, in a position to stabilize the tetrahedral intermediate formed by attack of 
water at the peptide scissile bond (Addlagatta et al., 2006; Thompson et al., 
2006).  However, in ERAP1, Tyr438 is found oriented away from the substrate 
binding site, as a result of reorientation of the interfacial helix and adoption of a 
different rotameric form than found in the other M1-aminopeptidase structures 
(Figure 2.9). 
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Figure 2.9. Conservation of Catalytic Residues Among M1 Family 
Aminopeptidase Structures. Conservation shown in overlay of the active sites 
of human leukotriene hydrolase, LTA4H (cyan, PDB 3FUH), C. psychrerytheaea 
cold active aminopeptidase, COLAP (yellow, PDB 3CIA), E. coli aminopeptidase 
N, ePepN (pink, PDB 2HPT), P. falciparum aminopeptidase M1, PfAM1 (purple, 
PDB 3EBG), T. acidophilium tricorn interacting factor F3, TIFF3 (grey, PDB 
1Z5H), and human ER aminopeptidase 1, ERAP1 (green). ERAP1 and TIFF3 
have an altered orientation of Tyr438 relative to the other aminopeptidases 
(arrows).  Residue numbers correspond to ERAP1. 
71
 
Substrate Specificity 
 ERAP1 is unusual among aminopeptidases in its ability to accept large 
peptide substrates up to ~16 residues.  Optimal activity is observed for peptides 
of ~10 residues, while most peptides of 8 or fewer residues are not processed as 
efficiently (Chang et al., 2005).  ERAP1 has a large cavity that provides a 
potential binding site for such large peptides, formed at the interface between the 
concave surface of domain II carrying the active site and the concave surface of 
the domain IV helical bowl (Figures 2.6).  A closer view of the cavity in the vicinity 
of the active site is shown in Figure 2.10.  The cavity is relatively narrow near the 
active site (upper left in Figure 2.10) and widens as it enters domain IV.  The 
wider part of the cavity can accommodate the C-terminal portion of polypeptide 
substrates bound with their N-terminal regions in position to be processed at the 
active site.  Two possible paths for long peptides are indicated in Figure 2.10. 
The heads of the arrows are located ~27 Å from the zinc atom, corresponding 
approximately to the length of an extended 7-8 residue peptide. Due to the 
sequestered nature of the active site in domain II, and the arrangements of 
domains I and IV around the mouth of the cavity, it is unlikely that ERAP1 can 
complete the processing of an epitope peptide precursor while it is bound to 
MHC class I. Docking experiments show that the closest possible approach of 
the amino terminus of a peptide bound to a MHC class I protein to the zinc center 
in ERAP1 is 20 Å, corresponding to at least 6 residues of extended polypeptide. 
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Figure 2.10. Surface Polarity of ERAP1 in the Substrate Binding Site. The 
substrate binding cavity extends from the active site into domain IV.  The surface 
of ERAP1 near the active site is colored by polarity. The polar residues are green 
and hydrophobic residues are white. The catalytic zinc is shown as a dark gray 
sphere, and bestatin has cyan bonds. Expected positions of peptide side chain 
binding pockets S1 and S1’ are indicated. Arrows represent possible paths of 
peptides extending from the active site into the cavity. 
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 The orientation of bestatin in the aminopeptidase active site can help to 
identify subsites in the active site region that accommodate peptide side chains 
(Fournie-Zaluski et al., 2009; Tholander et al., 2008; Thunnissen et al., 2001).  
Following peptidase convention, we call the site responsible for accommodating 
the peptide side chain N-terminal to the cleavage site S1, and subsequent 
positions called S1’, S2’, etc.  Bestatin’s phenyl group binds into the 
aminopeptidase S1 site, with its isobutyl group oriented toward the S1’ site 
(Figure 2.8).  In ERAP1, the S1 site is a relatively shallow hydrophobic pocket 
lined by the side chains of Ser316 and Met319 of the GAMEN loop, and Gln181 
and Glu183 of the D1 loop (Figure 2.8).  Modeling indicates that a leucine, 
methionine, or isoleucine would fit closely into the S1 pocket as the first residue 
of a bound peptide.  Larger residues such as tryptophan and arginine can make 
similar contacts, but only by adopting rotamers that orient the side chain out of 
the pocket. Smaller residues can be accommodated but would leave voids within 
the site.  This pattern matches the N-terminal specificity observed in peptide 
hydrolysis and antigen presentation studies where peptides with amino-terminal 
leucine, isoleucine, and methionine residues were processed most efficiently, 
while those with amino-terminal tryptophan, arginine, and cysteine were 
processed less efficiently (Chang et al., 2005; Evnouchidou et al., 2008; Hearn et 
al., 2009; Saveanu et al., 2005; Serwold et al., 2001).  The broader reactivity 
towards peptides as compared to single residue substrates likely reflects the 
contribution of binding sites for peptide side chains beyond S1’, which can 
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compensate for non-optimal interactions in the sterically rather permissive S1’ 
pocket. 
 ERAP2, another ER aminopeptidase also involved in ER antigen 
processing (Saveanu et al., 2005; Tsujimoto and Hattori, 2005), has a different 
specificity than ERAP1, with greatly increased preference for fluorogenic amino 
acid substrates (Chang et al., 2005; Tanioka et al., 2003) and peptides (Saveanu 
et al., 2005) carrying N-terminal Arg and Lys groups. One difference between 
ERAP1 and ERAP2 in this region is at position 181, which is Gln in ERAP1 but 
Asp in ERAP2.  Residue 181 forms the top of the S1 pocket (Figure 2.8), and the 
Gln to Asp substitution would have the effect of lengthening the pocket and 
making it more acidic.  A site specific mutant of ERAP1 carrying a Gln181 to Asp 
substitution alters its specificity from hydrophobic towards basic amino acids 
(Goto et al., 2008). 
 ERAP1 has been shown to be unable to trim peptides with a proline 
residue as a second amino acid (Hearn et al., 2009; Serwold et al., 2001).  
Modeling of proline into a mock peptide substrate indicates that the side chain 
cannot be accommodated into the S1’ site without disrupting the GAMEN loop 
and arrangement of catalytic residues above the nitrogen of the scissile peptide 
bond.  
 ERAP1 exhibits sequence specificity for other regions of the substrate 
beyond its N-terminus, as shown by alanine scanning and library screening 
studies (Evnouchidou et al., 2008).  Without a structure of ERAP1 bound to a 
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peptide substrate, identification of the sites responsible for this sequence 
specificity is speculative, however several aspects of the internal cavity are 
consistent with it being a binding site for long peptide substrates.  Figure 2.11 
shows a top view of ERAP1, represented as an electrostatic potential surface.  
Dashed lines show approximate distances of 20 Å and 30 Å from the zinc atom in 
the active site.  The overall negative charge of the cavity in this region is 
consistent with internal specificity for positively charged residues observed at 
several sites in a 9-mer peptide substrate (Evnouchidou et al., 2008).  Shallow 
pockets within the overall substrate binding cavity, visible as depressions along 
the sides of the groove shown in Figure 2.10, potentially correspond to pockets 
for peptide side chains, and could be responsible for ERAP1’s observed 
preferences for hydrophobic residues at the C-terminal position of peptide 9-mers 
(Evnouchidou et al., 2008) and 10-mers (Chang et al., 2005).  Other binding sites 
for peptide side chains may be present on the interior faces of helices lining the 
cavity, as observed for other proteins carrying armadillo/HEAT repeat motifs 
(Monecke et al., 2009). 
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Figure 2.11. Electrostatic Surface Map of ERAP1.  Surface colored from red to 
blue represents negatively charged to positively charged regions. Dotted lines 
represent indicated distances from zinc ion (grey sphere). Bestatin colored with 
cyan bonds.  Figure generated using DelPhi (Nicholls and Honig, 1991)  and 
PyMol (DeLano, 2008). 
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Domain Motions 
 ERAP1 has a significantly more open structure than other M1 family 
members because of the orientation of its C-terminal helical domain relative to 
the remainder of the protein (Figure 2.12). In LTA4H and ColAP, the small C-
terminal helical domain packs closely against the catalytic domain, with no 
intervening small β-sandwich domain and no extensive cavity formed.  For 
ePepN, and PfAM1, the helical C-terminal domain is relatively large and similar in 
overall dimensions to that of ERAP1. However, it packs closely against the active 
site, forming a closed substrate binding cavity.  TIFF3 has a more open domain 
arrangement somewhat similar to that of ERAP1, but with the C-terminal domain 
packing closer to the catalytic domains, forming a smaller cavity.  In the structure 
of ERAP1, domain IV extends away from the active site, forming a cavity 
substantially larger than in the other structures, and more accessible to solvent.  
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Figure 2.12. Overall Fold of M1 family of Aminopeptidases. Structures of M1 
aminopeptidases family members and thermolysin are colored by domain. 
Aminopeptidases are shown in ribbon diagram and colored according to 
domains: blue is domain I, green is domain II, orange is the domain III, and red is 
domain IV. Dotted lines represent disordered loops. Zinc is represented as a 
black sphere. 
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 Among the three copies of ERAP1 in the crystallographic asymmetric unit, 
the interdomain orientations vary, with the differences mostly affecting the 
orientation of domain IV relative to the other domains.  Figure 2.13 (left) shows 
these three copies after superposition of domain III, revealing a small motion 
tending towards a more “closed” conformation. This motion differentially affects 
the C-terminal domain, with the tops of helices 15-24 moving closer to helices 9-
14 and the other protein domains (compare with Figure 2.2). This motion tends 
towards closing of the cavity.  A normal mode analysis (Suhre and Sanejouand, 
2004) (Figure 2.13 right), indicates that further closing motions along the same 
trajectory are accessible, which might allow ERAP1 access to a more closed 
orientation under certain circumstances.  
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Figure 2.13. Domain Movements. Hinge movement suggested by different 
inter-domain orientations among the three molecules observed in the ERAP1 
crystallographic asymmetric unit, shown here as C-alpha traces aligned at 
domain III (left). The right panel shows samples of ERAP1 motions as indicated 
by normal mode analysis, shown as C-alpha traces colored blue to red 
representing extremes of conformational alteration.  The ERAP1 structure is 
overlay in black. 
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Length-dependent trimming  
The length dependent trimming experiments were conducted by the laboratories 
of Alfred Goldberg and Efstratios Stratikos. ERAP1 processes peptides longer 
than 8-9 residues much more efficiently than shorter peptides (Chang et al., 
2005). This activity is unusual among aminopeptidases, which typically are most 
active in processing shorter peptides, but is consistent with ERAP1’s role in 
antigen processing.  One potential mechanism for this effect would be regulation 
of the enzyme’s activity depending on the length of bound peptide substrate.  To 
investigate this possibility, leucine-7-amido-4-methylcoumarin (L-AMC) was used 
to monitor ERAP1’s hydrolytic activity in the presence of peptides of varying 
lengths (Figure 2.14). The peptide used was a series of peptides based on the 
antigenic peptide SIINFEKL, which previously has been used to characterize 
ERAP1 activity in vitro (Chang et al., 2005; York et al., 2002) and in vivo (Hearn 
et al., 2009).  ERAP1’s L-AMC aminopeptidase activity was greatly increased in 
the presence of increasing SIINFEKL length variants up to eight residues (Figure 
2.14 A). These peptides themselves were not long enough to be processed 
efficiently by ERAP1 (Figure 2.14 A, lower panel). Activation of L-AMC hydrolysis 
decreased with increasing peptide length for SIINFEKL variants 8 residues or 
longer, which however were processed efficiently by ERAP1. This phenomenon 
was not unique to SIINFEKL, since a similar activation occurred with peptides 
carrying a poly-glycine motif of increasing length (Figure 2.14 B). Thus, they 
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showed that shorter peptides can act as allosteric activators of ERAP1, 
converting the enzyme to a more active conformation upon binding.  
 To investigate this phenomenon without potential complications from 
hydrolysis of the activating peptide, they used the non-hydrolyzable peptide L(N-
Me)VAFKRAF, LMe, as an allosteric activator (Figure 2.14 C). The sequence of 
this peptide was optimized for interaction with ERAP1 based on library screening 
(Evnouchidou et al., 2008).  In this peptide, the amide group of the first peptide 
bond carries a methyl group that should interfere with the catalytic cleavage of 
this peptide bond. Accordingly, the LMe peptide is not trimmed by ERAP1 under 
experimental conditions, although the unmethylated version of the peptide is an 
excellent ERAP1 substrate and is readily processed (Figure 2.14 C, compare left 
and right panels).  Increasing concentrations of LMe peptide activated ERAP1’s 
hydrolysis of L-AMC substrate (Figure 2.14 D). When the effect of LMe on ERAP1 
enzymatic activity was evaluated using a full-length fluorogenic 10-mer substrate 
(Evnouchidou et al., 2009) rather than L-AMC, a concentration dependent 
decrease in ERAP1 activity was observed (Figure 2.14 D). The ability of the LMe 
peptide to activate the hydrolysis of L-AMC but to competitively inhibit hydrolysis 
of a fluorogenic peptide substrate implies a simple mechanism in which the LMe 
peptide binds to a regulatory site that partially overlaps with the substrate-binding 
site, allowing concurrent binding for a small substrate like L-AMC while blocking 
binding for a larger one. 
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Figure 2.14.  Allosteric Activation of ERAP1. 
A.  ERAP1 activation of L-AMC hydrolysis by SIINFEKL variants (top)  and 
degradation of a series of truncated and extended SIINFEKL variants (bottom) 
B. ERAP1 activation of L-AMC hydrolysis by LG(n)L peptides (top) and  
degradation of a series of LG(n)L peptides.   
C. N-methylation of the first amide bond in peptide L, an optimized ERAP1 
substrate, blocks hydrolysis.  Reverse-phase chromatograms of peptides 
incubated in the presence or absence of ERAP1 shown.  Arrow indicates 
degradation product. LMe is resistant to degradation. 
D. ERAP1 hydrolysis of L-AMC is activated by LMe, an N-terminally blocked 
peptide with a sequence optimized for interaction with ERAP1. 
E. ERAP1 hydrolysis of a fluorescent peptide substrate is inhibited by LMe, the 
same peptide that activates L-AMC hydrolysis. 
F. Model for ERAP1 length dependent cleavage activity. Left. A short peptide 
(pentamer shown) cannot reach from the catalytic site to the regulatory site, and 
ERAP1 remains in the lower-activity open conformation.  Right. A long peptide 
(nonamer shown) can reach the regulatory site, inducing conversion to closed 
conformation with increased peptide hydrolysis activity. 
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 The existence of distinct yet nearby catalytic and regulatory sites within 
ERAP1, as suggested by the structural and biochemical evidence, allows us to 
postulate a simple model that can account for ERAP1’s unique properties as a 
length-dependent aminopeptidase (Figure 2.14 E). According to this model, 
peptides longer than ~8-9 residues can concurrently occupy the active and 
regulatory sites in ERAP1, leading to the enzyme activation and efficient 
trimming. Shorter substrates can either occupy the active site or the regulatory 
site, but not both at the same time. As a result, shorter substrates will be 
processed at a slower rate. In these model experiments, the very short substrate 
L-AMC could occupy the active site at the same time that a peptide (<10 
residues) occupies the regulatory site, leading to allosteric activation of substrate 
hydrolysis. Activation of L-AMC by peptides falls off for longer peptides, 
presumably due to limitations in size within the enzyme’s internal cavity. This 
model explains the efficiency of ERAP1 in trimming long substrates since such 
substrates can activate their own trimming. Furthermore, this model can explain 
the slow trimming rate for small substrates that are too short to self-activate the 
enzyme. Overall, this model is consistent with the biological role of ERAP1 in 
efficiently removing 1-7 residues from the N-terminus of antigenic peptide 
precursors with broad specificity but sparing many mature antigenic peptides. 
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Ankylosing Spondylitis Associated Polymorphisms  
 Ankylosing spondylitis (AS) is a chronic inflammatory joint disease with a 
strong genetic component that is strongly linked to the class I MHC allelic variant 
HLA-B27.  Genome-wide studies in many human populations have shown strong 
associations outside the MHC region (reviewed in (Brown, 2010)) in particular 
with a region encompassing the ERAP1 gene (Burton et al., 2007).  Figure 2.15 
shows sites of eight single nucleotide polymorphisms that are present in allelic 
variants of ERAP1 associated with altered risk of developing AS: R127P, M349V, 
D575N, K528R, Q730E, R725Q, V647I, and C736R (Burton et al., 2007; Harvey 
et al., 2009). Potential effects of some of these variants can be identified by 
examination of the structure of ERAP1. The ERAP1 polymorphism, K528R, has 
the highest odds ratio for decreased risk for AS (Reveille et al., 2010) and also 
has been associated with increased risk for hypertension (Yamamoto et al., 
2002).  A biochemical study of this variant showed that it reduces enzymatic 
activity in degrading single residue substrates and peptidic hormones (Goto et 
al., 2006). This residue is located on an exposed loop linking domains II and III, 
and potentially could interact with portions of the C-terminal domain after cavity 
closure as envisioned in Figure 2.15. The polymorphism M349V is associated 
with altered risk of AS.  Position 349 is near the active site, and would be able to 
interact directly with the peptide substrate.  R725Q and Q730E polymorphisms 
involve domain IV residues exposed on the inner surface of the cavity, and might 
affect peptide binding or domain closure. R127P creates an unusual PP 
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sequence at the tip of a loop in domain 1 that extends towards the cavity, and 
might cause conformational alteration.  The V647I polymorphism is located at the 
end of helix 10 at the interface with helix 24, near the interactions that close 
domain IV, and would be affected by domain reorientation. The C736R 
polymorphism could cause a structural change because Cys736 participates in a 
disulfide bond with Cys743 between helices 14 and 15 of domain IV.  D575N is 
located at the distal end of domain II, oriented away from ERAP1’s active site 
and cavity.  Although this position does not appear to be involved directly in 
substrate binding or catalysis, domain III in TIFF3 has been suggested to 
regulate domain motions controlling activity (Kyrieleis et al., 2005). These 
considerations indicate that ERAP1 polymorphisms around the active site, 
domain junctions, and C-terminal cavity could influence enzymatic activity of 
ERAP1 and may affect the repertoire of presented self and environmental class I 
MHC-bound peptides. 
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Figure 2.15. Ankylosing Spondylitis- Associated Mutations Mapped on 
Surface of ERAP1. Surface of ERAP1 is gray, with polymorphisms associated 
with ankylosing spondylitis shown in pink. Underlined residues are hidden in this 
view. 
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DISCUSSION 
The crystal structure of ERAP1 reveals an open, four-domain arrangement 
with a large solvent-accessible chamber contiguous to a zinc-based 
aminopeptidase active site. The large cavity appears to be an adaptation specific 
to ERAP1 and related to its ability to efficiently process peptides that are longer 
than the substrates of typical aminopeptidases. The ability of short peptides to 
allosterically activate ERAP1 towards the fluorogenic aminopeptidase substrate 
L-AMC suggests conversion between (at least) two different conformations 
dependent on peptide binding, one more and one less active.  The length-
dependent processing activity characteristic of ERAP1 probably reflects this 
same activation process, with peptides longer than 7-8 residues able to enhance 
their own amino-terminal processing.  Comparisons with other M1-family 
aminopeptidases suggest that the structure of ERAP1 bound to bestatin 
represents an open state not optimized for catalysis, but which could adopt a 
more closed arrangement by simple rigid-body domain motions.  Differences 
observed between three crystallographically independent copies of the molecule 
in the crystal and normal mode analysis of the refined structure suggest a 
trajectory for such a motion.  The concave surface of the C-terminal helical 
domain implies that after closure there would still be a cavity sufficient to 
accommodate a peptide substrate of up to 13-16 residues 
 How could conversion between the active and inactive conformations of 
ERAP1 be regulated? The arrangement of key functional groups in the active site 
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of ERAP1 is identical to that observed for other M1 family members, except for 
Tyr438, which is oriented away from the catalytic zinc in ERAP1 but towards it in 
most other M1 aminopeptidase structures (Figure 2.9).  The one other exception 
is TIFF3, which like ERAP1 is in an open conformation (Kyrieleis et al., 2005), 
and which also has the Tyr438 analog also oriented away from the active site 
(Addlagatta et al., 2006). In ERAP1, a small ~30-40º rotation of helix 5 would 
orient Tyr 438 towards the active site, in a position to participate in peptide bond 
hydrolysis chemistry. Structural studies of other enzymes related to ERAP1 
suggest that domain motions triggered by peptide binding could induce active 
site changes to enhance peptidase activity as suggested here.  In two 
multidomain zinc metallopeptidases distantly related to ERAP1, human 
angiotensin-converting enzyme-related carboxypeptidase (ACE2) (Towler et al., 
2004) and E. coli dipeptidyl carboxypeptidase (Dcp) (Comellas-Bigler et al., 
2005), domain closure motions have been associated with active site 
reorganizations favoring catalysis. In two single-domain zinc metallopeptidases 
more closely related to ERAP1, thermolysin (Holland et al., 1992) and astacin 
(Grams et al., 1996), sub-domain motions similarly reorient active site residues 
for hydrolysis. In the structure of ERAP1, domain closure could reorient helix 5 
and Tyr438.  Helix 5 is oriented towards the C-terminal domain, sandwiched 
between helix 3, which carries the second Glu of the HExxHx18E motif, and helix 
4, which packs against helix 10 of the C-terminal domain.  While no direct 
contacts between helix 5 and the C-terminal domain are observed in the 
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structure reported here, a disordered region for which we do not observe electron 
density extends from the end of helix 5 towards the C-terminal domain.  Two 
other disordered regions are found directly across the cavity, between the tops of 
helices 21 and 22, and between the tops of helices 23 and 24 (Figure 2.3). 
Domain closure along the trajectory indicated by normal mode analysis would 
bring these regions into contact.  
 A unique aspect of ERAP1 is its preference for long peptide substrates.  
Low-affinity, low-specificity binding sites on the interior surface of the cavity, 
similar to those present on nuclear importin-α,  another armadillo/HEAT repeat 
protein (Matsuura and Stewart, 2004), might enable efficient peptide capture in 
the open form. Cavity closure could help to align peptides towards the active site 
for amino-terminal processing, and differential exposure of interior binding sites 
between open and closed forms could facilitate peptide binding and release 
cycles, which would appear to be necessary for sequential removal of peptide N-
termini as a long antigenic precursor is processed. This type of mechanism has 
been suggested for insulin degrading enzyme, a dimeric chambered zinc 
endopeptidase with “exosites” for binding entrapped peptide at positions distant 
from the hydrolytic site (Malito et al., 2008; Shen et al., 2006).  Recently, 
ERAP1’s paralog, IRAP, has been shown to process relatively long peptides 
(Georgiadou et al., 2010). If this model is correct, then IRAP also would be 
expected to adopt open and closed conformations during catalysis.  
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 During the manuscript preparation, a crystal structure of ERAP1 without 
bestatin was independently determined by another group (Figure 2.16). That 
structure reveals ERAP1 in a closed conformation similar to that observed for 
LTA4H, ColAP, ePepN, and PfAM1, with the C-terminal domain closed into the 
catalytic domain (Figure 2.16D) and with Tyr438 oriented towards the active site 
to allow for participation in peptide bond hydrolysis (Figure 2.16E).  In the closed 
conformation, the substrate binding pocket is still large enough to accommodate 
a 12-14-residue peptide, but it is no longer accessible from the exterior of the 
protein (Figure 2.16C,F), having been closed off by motion of helices 18-24 in the 
C-terminal domain (Figure 2.16B,E).   The loop connecting helices 21 and 22 
contacts the loop between helices H5 and H6, providing a possible route for 
peptide-induced conformational changes to be communicated to the vicinity of 
the active site.  Together the two structures of ERAP1 provide clear evidence of 
a large conformational change associated with opening the substrate binding site 
and coupled to active site reorganization, previously suggested for other M1 
family members (Addlagatta et al., 2006).  ERAP1 is thus first M1-
aminopeptidase for which structures are available in both open and closed 
conformations, and is likely to serve as a prototype for understanding regulation 
of enzyme activity in this entire class of proteases. 
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Figure 2.16. Open and Closed Conformations of ERAP1.   
A., B., C.  ERAP1-bestatin in an open conformation as reported here (PDB 
2MDJ). 
D., E., F., ERAP1 in closed conformation as reported in a recent crystal structure 
(PDB 2XDT).  
A., D. Ribbon diagrams 
B. E. The close-up views of active site is shown here with zinc atom shown in 
gray, model peptide substrate with white bonds, and Tyr438 with yellow bonds.  
ERAP1 helices are shown as cylinders and colored according to domain. 
E,F. Cutaway view of peptide binding cavity, with surface of cavity shown in gray, 
zinc atom in dark gray, and model peptide substrate with white bonds. 
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 Based on the ERAP1 crystal structure, length and sequence specificity, 
allosteric regulation by peptides, and comparison with other M1-family proteases, 
we can describe a likely mechanism for ERAP1 processing of antigenic 
precursors.  (1) Antigenic precursor peptides can access and bind to the groove 
while the protein is in an open conformation, using interactions at N-terminal S1 
and S1’ sites but also interactions at other sites in the chamber.  Active site 
residues are not in the optimal arrangement. (2) Peptide binding with occupancy 
of the regulatory site causes domain closure around the bound peptide and 
conversion to the optimal active site constellation, possibly with reorientation of 
Tyr438.  Interactions responsible for triggering this change are not yet clear, but 
likely involve portions of the substrate ~7-8 residues away from the N-terminus, 
and (directly or indirectly) ERAP1 residues located near domain boundaries.  (3) 
Catalysis.  Based on studies of similar metalloproteases, catalytic steps would 
include: attack of the scissile amide bond by a zinc-bound water, activated by 
conserved Glu354, to form a tetrahedral intermediate stabilized by interactions 
with active site residues, followed by collapse of the tetrahedral intermediate with 
proton transfer to generate a free amino acid and new peptide N-terminus.  (4) 
Release of products after hydrolysis, and substrate rebinding for next cycle.  
Liberation of the cleaved N-terminal amino acid potentially could occur without 
conversion to an open form if an exit channel exists in the closed structure, but 
more likely the protein at least partially converts to an open form after hydrolysis. 
Interaction of the cleaved peptide product with low-specificity binding sites could 
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facilitate rebinding in a shifted frame in preparation for the next catalytic cycle. (5) 
When peptide substrates are trimmed beyond ~8-9 residues, they are too short 
to engage both regulatory and active sites, and cannot be processed efficiently.  
 The crystal structure of ERAP1 bound to bestatin provides insight into 
ERAP1’s unusual length specificity and its peptide sequence preferences. These 
intrinsic properties of ERAP1 probably contribute along with MHC-binding 
protection to the length and sequence distribution of MHC class I bound 
antigens.  Disease-associated ERAP1 polymorphisms involve residues located 
near putative substrate binding and regulatory sites. One model for the 
pathogenesis of AS proposes that particular self peptides presented by HLA-B27 
may mimic those of environmental flora, so that T cells originally recognize 
epitopes in an inflammatory context and subsequently respond to self peptides in 
an autoimmune fashion.  Altering peptide trimming by ERAP1 variants may lead 
to altered levels of such arthritogenic self peptides or of their mimics, or may lead 
to altered generation of T cell clones in the thymus. Other studies have linked 
ERAP1 SNPs to predisposition to diabetes type I, although weakly (log odds 
1.07) (Fung et al., 2009), and to the clinical outcome of cervical cancer that is 
caused by HPV infections (Mehta et al., 2009). These associations could involve 
constructive or destructive processing of specific peptides, and further studies of 
these variants are warranted.   
Overall, it appears that both the overall conformation of ERAP1 as well as 
its ability to be activated by long substrates are features that the enzyme has 
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evolved in order to process large antigenic precursor peptides, while at the same 
time sparing peptides of length suitable for MHC binding.
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CHAPTER 3 
Structural Analysis of MHCII, HLA-DR1, in Complex with an 
Environmentally Sensitive Peptide, (4-DAPA)-HA 
The work described in this chapter is part of a publication where I am the second 
author. I did the crystallography and was involved with the Il-2 bioassay to study 
T cell activation by one of environmentally sensitive probes studied in the 
publication, Venkatraman P, Nguyen TT, Sainlos M, Bilsel O, Chitta S, Imperiali 
B, Stern LJ. Fluorogenic probes for monitoring peptide binding to class II MHC 
proteins in living cells. Nat Chem Biol. 2007 Apr;3(4):222-8.  
 
INTRODUCTION
The MHC-bound antigen repertoire on the cell surface is responsible for 
eliciting a T cell response that is necessary to defend foreign evasions in 
organisms. Class II MHC molecules present antigenic peptides at the cell 
surface. Antigen loading onto class II MHC occurs predominantly in endosomes 
where the invariant chain gets cleaved and replaced by a peptide by a 
mechanism that involves HLA-DM. This process is spatially and developmentally 
regulated (Kleijmeer et al., 2001; Pierre et al., 1997). Real time visualization of 
this process has been difficult because of the tools available requires many 
experimental caveats such as not knowing how much is unbound due to the 
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experimental washes when using radio-labeled or GFP labeled peptides or 
antibody specific for a particular complex (Day et al., 1995; Murphy et al., 1992).  
Class II MHC molecules hold peptides in its peptide binding groove in a 
polyproline type II conformation through interactions between peptide main chain 
and MHC main and chain and side chain interactions (Stern et al., 1994). 
Additionally, the peptide binding groove consist of allele-specific pockets that 
accommodate side chains of the bound peptide. Class II MHC binds peptides 
with lengths from 13 to 25 residues long where 9 to 11 residues interact with the 
MHC molecule and the terminus flanks out on both ends of the peptide binding 
groove (McFarland and Beeson, 2002). For HLA-DR, the most abundant of the 
three human class II MHC proteins (HLA-DR, HLA-DP, HLA-DQ), the major 
determinant of peptide binding is a large hydrophobic pocket (P1 pocket) that can 
accommodate a hydrophobic or aromatic amino acid side chain near the amino 
terminus of the peptide (Jardetzky et al., 1990; Sato et al., 2000).  Other 
specificities in the binding groove are at pockets, P4, P6 and P9, with the fine 
specificity varying between MHC allelic variants (McFarland and Beeson, 2002; 
Stern et al., 1994).  
The side chain specificities of the side chain binding pockets in HLA-DR1 
have been well characterized. Specifically, conserved aliphatic and aromatic 
amino acids line the P1 pocket giving it a non-polar hydrophobic environment 
(Stern et al., 1994). Taking advantage of the known properties of the P1 pocket, 
we investigate the possibility developing a fluorogenic probe for that pocket. 
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There have been reports of solvatochromic probes where an environmental 
change induces large spectral changes exhibited by the chromaphore. Peptides 
consisting of the peptide analog probes have been used to phosphotyrosine-
binding SH2 (Vazquez et al., 2005), phosphoserine/phospothreonine-binding 14-
3-3 domains (Eugenio Vazquez et al., 2004), RNAase assembly (Nitz et al., 
2002), delta-opioid antagonist binding (Chen et al., 2006) and electrostatics 
within protein G (Cohen et al., 2002).  
Our studies suggest that replacing the P1 pocket residue of the HA 
peptide with the solvatochromic probe, 4-DAPA, provides a suitable peptide for 
antigen processing studies. It demonstrates that the modified HA peptide binds to 
the class II MHC with the same affinity and activate HA specific T cells similarly 
as the native HA peptide. It also bound to HLA-DR1 in the same register and did 
not effect the overall fold of HLA-DR1. 
 
MATERIALS AND METHODS 
All reagents for peptide synthesis were of analytical grade. Resin and 
amino acids were obtained from AnaSpec (USA). Amino acid and reagents were 
obtained from Novabiochem and Sigma-Aldrich.  4-DAP, 4-DAPA, were 
synthesized according to the previously reported methods by the Imperiali 
laboratory (Eugenio Vazquez et al., 2004; Vazquez et al., 2005). 
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Peptide synthesis and purification 
The (4-DAPA)-HA peptide made from HA peptide that was synthesized on 
a Rink-amide resin using an automatic peptide synthesizer adopting standard 
Fmoc-based SPPS chemistry by Prasanna Ventraman. The 4-DAPA were then 
coupled manually to 0.01 to 0.02 mmol resin-bound peptide. Two equivalents of 
Fmoc-amino acid were mixed with two equivalents each of N, N-
Diisopropylethylamine /2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl 
uronium hexafluorophosphate Methanaminium in 0.30 mL 
dimethylformamide (DMF) and reacted with the resin for 60 min. The peptides 
were deprotected (20% piperidine in DMF) and N-acetyl capped using a mixture 
of pyridine and acetic acid (0.15 M in DMF, 30 min). For peptide 4-DAPA-HA, the 
remaining Lys and Pro residues were coupled manually after Fmoc-4-DAPA 
addition and deprotection. Peptides was cleaved from the resin and ether 
precipitated and washed before purification by reverse phase HPLC 
(water/0.01% TFA using an acetonitrile/0.01% TFA gradient). The major peak 
was collected, dried and re-suspended in water at pH 4.0 or in water containing 
100 mM urea. MALDI-TOF confirmed the identity of the peptides (Ac-4-DAPA 
peptide amide: expected 1089.54 Da; observed mass 1090.69 Da). Peptides 
were stored frozen at -80°C until use.   
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MHC-peptide complex formation 
Soluble recombinant DR1 extracellular domain was prepared by 
expression of truncated HLA-DRA*0101 and HLA-DR1*0101 genes in S2 insect 
cells cultured in serum-free medium followed by immunoaffinity isolation of the 
secreted protein as described (Stern and Wiley, 1992). For peptide loading, 7 µM 
of HLA DR1 was incubated with 30 µM (4-DAPA)-HA in PBS (10 mM Na2HPO4 
containing 137 mM NaCl and 2.7 mM KCl, (pH 7.4), 1 mM PMSF, protease 
inhibitor cocktail from Sigma Aldrich, 0.02% sodium azide) for 3 days at 37°C. 
MHC-peptide complexes were isolated by gel filtration using a Superdex S200 
column (Pharmacia) with phosphate-buffered PBS containing 0.02% sodium 
azide buffer. The MHC-peptide complex eluting between 31 and 34 min was 
collected and concentrated. Non-bound protein tends to aggregate under the 
incubation conditions and is typically not found in these fractions (Stern et al., 
1994). The complex thus purified from free peptide was stable for several months 
at 4°C.  UV-Visible spectra of the purified peptides and the HLA-DR-peptide 
complex were measured in PBS.  Fluorescence excitation and emission spectra 
were obtained for purified DR-peptide complex and the free peptide, with 5 nm 
bandpass for excitation /emission. Raman spectra of pure water obtained under 
the same conditions were generally subtracted from the original spectra. For 
direct binding measurement in presence of excess peptide, the 4-DAPA-peptide 
(1 µM) was incubated with 0.125 - 1 µM of HLA-DR1 for 3 days and the 
fluorescence measured as described above.  
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Crystal structure 
HLA-DR1 extracellular domain was produced by expression of the α and β 
subunits in E. coli followed by in vitro folding, peptide loading, and final isolation 
by gel filtration, as described (Frayser et al., 1999). The bacterial superantigen, 
SEC3-3B2, was expressed in folded form in the E. coli periplasm and isolated as 
described(Andersen et al., 1999). A 1:1 mixture of HLA-DR1-(4-DAPA)-HA and 
SEC3-3B2 was crystallized by vapor diffusion against 100 mM sodium acetate, 
2% PEG 4K and 10% ethylene glycol at 4°C. A 100 µm cubic crystal was 
transferred to 25% ethylene glycol v/v in mother liquor and cooled to -190°C for 
data collection at the National Synchrotron Light Source beamline X-29 using 1.1 
Å radiation. Diffraction data were processed using HKL2000 (Otwinowski, 1997) 
and phased using a HLA-DR1-SEC model from the  2.1 Å crystal structure of 
another peptide complex (PDB 1PYW). Initial unrefined omit maps exhibited 
clear density for the DAPA side chain that extended only to the middle of the aryl 
ring, and smeared density for the Pheβ89 side chain.  Initial model excluding 
DAPA and Pheβ89 was improved by several cycles of manual rebuilding, 
automated refinement using Refmac and TLS (Vagin et al., 2004) or CNS 
(Brunger, 2007) and addition of ordered water molecules. Omit maps from the 
improved models exhibited improved 4-DAPA and Pheβ89 side chain density. 
The 4-DAPA topological parameters and refinement restraints were obtained 
from the PRODRG server (Schuttelkopf and van Aalten, 2004), and use to 
include 4-DAPA in the model.  Examination of positive and negative electron 
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density in Fobs-Fcalc difference maps suggested a possible minor alternate 
orientation of the 4-DAP ring corresponding to a c2 rotation of ~180º, with a 
corresponding motion of Pheβ89. However, inclusion of this alternate 
conformation at various occupancy levels did not improve the refinement 
statistics or appearance of the electron density, therefore it was not included in 
the final model. Data collection and refinement statistics are shown in Table II.  
Coordinates for this model have been deposited in the PDB and is available with 
ID 2IPK. 
 
Mass Spectrometry 
About 5-6 crystals were looped out of a crystal drop and placed in water to 
remove excess peptide that might be outside of the crystals. Next the crystals 
were dissolved in 10% acetic acid in water. The mixture was either purified using 
C18 zip tip (Millipore) then spotted or spotted directly with alpha-cyano-4-
hydroxycinnamic acid for Maldi-TOF mass spectrometry analysis.  
 
T cell activation 
A murine T cell hybridoma carrying the HLA-DR1-restricted HA [316-318] 
peptide-specific T cell receptor HA1.7 and human CD4, a kind gift of Jerome Bill 
(Univ. Colorado Health Sciences Center), was used to evaluate the biological 
activity of the modified HA peptide. This assay was carried out my Mauricio 
Calvo-Calle and myself. HLA-DR1+ B-lymphoblastoid LG-2 cells (20,000 per well 
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in 0.1 mL) were pulsed (in triplicate) with the indicated concentration of peptide 
for 3.5 hours at 37°C, 5% CO2 in RPMI medium supplemented with 10% FBS. 
After incubation the cells were washed 5 times with fresh medium, and then 
10,000 T cells were added in the same medium for an additional incubation of 24 
hours under the same conditions as above. Supernatants were removed and 
assayed for secreted IL-2 using the IL-2 dependent cell line CTLL-2 and a 3H-
thymidine incorporation assay.   
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RESULTS 
Modeling studies were conducted using the crystal structure of HLA-DR1 in 
complex with the influenza-derived HA peptide (PKYVKQNTLKLAT) (Stern et al., 
1994). The peptide tyrosine that occupies the P1 pocket was replaced with three 
amino acid analogs that consist of environment-sensitive fluorophores as the 
side chains. The amino acid analogs are termed 6-dimethylamino-2’-naphthoyl-
alanine (DANA/ALADAN) (Cohen et al., 2002; Nitz et al., 2002), 4-N,N,-
dimethylaminophthalimido-alanine (4-DAPA) (Eugenio Vazquez et al., 2004), and 
6-N,N-dimethylamino-2,3-napthalimido-alanine (6-DMNA) (Vazquez et al., 2005).  
The amino analogs 4-DAPA and 6-DMNA could be accommodated into the P1 
pocket of HLA-DR1 without major distortion of the MHC protein but 
DANA/ALADAN was too long to fit as suggested by molecular modeling 
consisting of rigid body docking and torsional angle adjustment. 
Although modeling suggest that the 4-DAPA or 6-DMNA group may fit into the 
P1 pocket, it is important that the introduction of these fluorescent reporter group 
in a modified peptide would not significantly alter the structure of the MHC-
peptide complex or its function in eliciting a T cell response.  To evaluate these 
issues, the HA peptide was synthesized with the P1 tyrosine replace with 4-
DAPA and termed 4-DAPA-HA.  The 4-DAPA-HA peptide bound well to HLA-
DR1 with an IC50 less than 1 nM in a standard competition binding assay. 
Fluorescence intensity, Emission lmax exhibited a blue shift and fluorescence 
intensity increased upon binding to HLA-DR1 (Figure 3.1). Lifetime 
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measurements (measured by Imperiali Lab) were 3.65 nsec for the majority 
fraction of the bound and 0.2 nsec for the majority fraction of the unbound (4-
DAPA)-HA. Additionally, the biological activity of the 4-DAPA-HA was studied. 
HLA-DR1-positive B cells were treated with HA or 4-DAPA-HA and used to 
stimulate an HLA-DR1-restricted HA peptide-specific T cell hybridoma.  An IL-2 
bioassay suggests that HA and 4-DAPA-HA treated B cells caused identical 
activation (Figure 3.2). To verify that 4-DAPA-HA binds into the peptide binding 
groove and check for any structural alterations of HLA-DR1 resulting from 
introduction of the 4-DAPA group, the crystal structure of the HLA-DR1:4-DAPA-
HA complex was determined at 2.3 Å resolution, using the bacterial 
superantigen, SEC3-3b2, to promote crystallization. Data collection and 
refinement statistics are shown in Table 3.I. The HA and (4-DAPA)-HA peptides 
adopt essentially identical conformations bound to HLA-DR1 (RMSD 0.24 Å) with 
differences observed only at the termini of the flexible and solvent-exposed Lys, 
Val and Lys side chains at the P-1, P2 and P8 positions, respectively (Figure 
3.3). As anticipated, the 4-DAP side chain occupies the P1 pocket completely 
buried by interactions with many aromatic and hydrophobic side chains in this 
region (Figure 3.4). We had expected that the 4-DAP side chain would displace 
one or two of the water molecules bond in the P1 pocket that form hydrogen 
bonds to the Thr89β hydroxyl group, however the structure reveals that 4-DAP 
predominately adopts the ring-flipped orientation, placing the dimethylamino 
group on the other side of the ring interacting with the Thrβ89 methyl group, and 
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not displacing the water molecules (Figure 3.4). Since initial electron density map 
only showed density up to the middle of the aryl ring in 4-DAP, crystals were 
tested for peptides. To ensure that the peptide crystallized was 4-DAPA-HA, 
peptides were extracted from crystals and analyzed by Maldi-TOF mass 
spectrometry showed no sign of native HA peptide (Figure 3.5). Overall, the 
introduction of the 4-DAP fluorophore in the context of (4-DAPA)-HA does not 
significantly alter the binding affinity, biological activity, or binding register 
compared to that of the HA peptide.  
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Figure 3.1. The (4-DAPA)-HA Peptide Exhibits a Spectral Shift when Bound 
to HLA-DR1. The (4-DAPA)-HA peptide was incubated with HLA-DR1 in 5 molar 
excess and the complex formed was purified by gel filtration. Fluorescence of 
DR-(4-DAPA)-HA was compared with the free peptide. 
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Figure 3.2. The (4-DAPA)-HA Peptide Stimulates HA Specific T cells 
Similarly as Compared to Native HA Peptide. HA (circles) or DAPA-HA (open 
squares) peptides. T cell activation measured using a bioassay for IL-2 
production. 
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Figure 3.3. The (4-DAPA)-HA Binds into HLA-DR1 in the Same Register as 
the Native HA Peptide. The panels show the peptide binding groove of 
structures of 4-DAPA-HA (top) or HA (bottom) peptide complex with HLA-DR1. 
HLA-DR1 is shown in surface representation with peptides shown in sticks. (Top) 
DAPA side chain is shown with yellow bonds extending down into the P1 pocket. 
(Bottom) Unmodified HA peptide from the crystal structure of the DR1-HA-SEC 
complex (PDB 1JWU) shown after alignment of MHC peptide binding domain, 
with tyrosine side chain at the P1 position shown with cyan bonds. 
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Figure 3.4. The 4-DAPA Binds into the P1 Pocket. Left panel shows |2Fo-Fc| 
omit map of the region around the P1 pocket with all residues shown removed 
from the model before map calculation. The (4-DAPA) group is colored in yellow. 
Right panel is a cut off section through the P1 pocket surface in gray, showing 
the HA peptide tyrosine side chain and the 4-DAPA fluorophore, along with their 
corresponding ordered water molecules. Unmodified HA peptide tyrosine from 
the crystal structure of the DR1-HA-SEC complex (PDB 1JWU). 
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Figure 3.5. Maldi-TOF Mass Spectrometry Spectra of Peptide Eluted from 
HLA-DR1/(4-DAPA)-HA Peptide/SEC3-3b2 Crystals. Top panel shows spectra 
of sample eluted from crystals and bottom shows a spectra of free purified 
peptide. Both panels show the expected molecular weight of (4-DAPA)-HA of 
1641 Da and sodium conjugated peak. 
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DISCUSSION 
The work discussed in this chapter is part of the characterization and an 
application of environmentally sensitive probes (4-DAPA and 6-DMNA) that can 
be use for antigen processing studies. The 4-DAPA containing peptide binds to 
HLA-DR1 and activates T cells similarly to that of non-modified peptides. The (4-
DAPA) peptide exhibits differential fluorescence properties with increase in 
lifetimes when bound to HLA-DR1 compared to the unbound form. Even though 
the structure of (6-DMNA) containing peptide has not been determined, it is 
expected that (6-DMNA) containing peptide will behave similarly to (4-DAPA) 
peptide because other characteristics such as lifetime increase, fluorescence 
intensity increase, peptide binding and T cell activation are essentially identical.  
In addition to characterizing these fluorogenic peptides, my coauthors also 
used the DAPA-HA peptide to study immature and mature DCs that previously 
used indirect methods of measuring peptide loading by antibodies for specific 
peptide MHC complexes. Our study using a direct method for measuring bound 
antigens to an MHC is in agreement with one of two fields of thoughts in regards 
to DCs as antigen presenting cells. The results suggest that immature DCs can 
present antigen sufficiently at the cell surface in contrast to other studies that 
suggest maturation is necessary for DCs to load antigen and present at the cell 
surface. However, our study does not distinguish the difference between loading 
of peptide at the cell surface or inside endosomes. It is important to understand 
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the spatial aspect of antigen loading in DCs to understand their role as antigen 
presenting cells.  
  Environmentally sensitive peptides, such as DAPA-HA, can be used to 
study other protein to peptide interaction such as phosphotyrosine-binding SH2 
domain (Vazquez et al., 2005) phosphoserine- and phosphothreonine-binding 
14-3-3 proteins (Vazquez et al., 2005). Though these peptides were designed 
and characterized for HLA-DR1 P1 binding pocket, they can be used in other 
class II MHC or allelic variants, such as HLA-DR4, HLA-DP and HLA-DQ, that 
have a pocket similar to the large hydrophobic P1 pocket. Additionally, since 
these probes are insensitive to pH and can be used in any cell type, they can be 
used to study HLA-DM peptide binding, regulation or antigen differential 
compartmentalization in the endosomes. Our characterization shows that the 
peptide probes consisting of 4-DAPA and possibly 6-DMNA can provide a direct 
way to measure peptide binding into class II MHC in suitable cellular 
environments. 
 Another application for this is to study class I antigen loading. Class I MHC 
such as H2-Kd (Rammensee et al., 1995) prefers a hydrophobic residue at the 4th 
position away from C-terminus of its peptide substrate. It can be used to study 
the antigen loading complex associated with class I MHC in the ER.  
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Table 3.1. Data collection and refinement statistics for DR1/(4-DAPA)-HA 
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CHAPTER 4 
Structural Study on the Determinants of the C-terminal Hairpin Loop of the 
GagP16 Peptide in the Binding Groove of HLA-DR1 
 
INTRODUCTION 
This chapter reports results to further understand the nature of a unique hairpin 
loop exhibited by an HIV derived peptide, GagP16 using X-ray crystallography 
and series of peptides designed that differ in sequence at the N-terminus of the 
peptide.  
The class II major histocompatibility complex, human leukocyte antigen 
(HLA)-DR1, plays an important role in the immune system because HLA-DR1 
presents antigenic peptides on cytotoxic cell surfaces for T cell recognition, thus 
initiating an immune response. It is the most abundant of the three human class 
II MHC proteins, HLA-DR, HLA-DP, and HLA-DQ. HLA-DR1 contains a 33-kDa α 
chain and a 28-kDa β chain. Each chain includes an IgG-like domain and 
together the chains make up the binding groove for antigenic peptides (Stern et 
al., 1994) Furthermore, these antigenic peptides exhibit polyproline type II 
conformations in the groove, which is enforced by interactions between 
conserved residues of HLA-DR1 and the backbone of the antigenic peptide 
(McFarland and Beeson, 2002; Stern et al., 1994) The binding groove stretches 
at least 9 amino acid residues long with specific residue recognition (Jardetzky et 
al., 1990). However, HLA-DR1 can present peptides longer than 20 amino acids 
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where the C- or N-terminus of the peptide hangs out of the binding groove (Chicz 
et al., 1992; Rudensky et al., 1991). Pockets formed in the peptide binding 
groove of HLA-DR1 allows for substrate specificities in the P1, P4, P6/7, P9 and 
P10 pocket (Stern et al., 1994).  The P1 pocket allows for large hydrophobic 
residues such as Tyr, Trp, Phe, Leu and Ile; P4 prefers aliphatic residues, P6 
allows small residues such as Gly, Ala, Ser and Pro, P9 prefers aliphatic and P10 
allows hydrophobic residues (McFarland and Beeson, 2002; Stern et al., 1994; 
Zavala-Ruiz et al., 2004a; Zavala-Ruiz et al., 2003). Peptide residue numbering 
starts at the P1 hydrophobic pocket. Residues towards the N-terminus of the 
peptide, which are outside the pocket, are numbered P-1, P-2, etc. Residues that 
are not in the binding pockets of HLA-DR1 shown to be important for T cell 
binding are the P-1, P3, P5 and P8 residues (Hennecke and Wiley, 2002; 
Wedderburn et al., 1995). Although structural information on HLA-DR1 in 
complex with the T cell receptor (TCR) can provide information on T cell 
recognition, there are limited structures peptide bound MHC complex with TCR.  
Bound to HLA-DR1, the HIV gag envelope derived peptide, GagP16 
(residues 34-48, PEVIPMFSALEGATP), exhibits a unique C-terminal beta hairpin 
loop that is required for T cell activation as shown by structural analysis and 
peptide mutation T cell activation studies (Zavala-Ruiz et al., 2004b). A truncated 
GagP16 termed GagP13 (PEVIPMFSALEG) does not elicit a T cell response but 
does bind to T cells more weakly (Norris et al., 2006; Zavala-Ruiz et al., 2004b).  
Crystallographic studies of HLA-DR1 and gag envelope derived peptides, 
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GagP13 and GagP16, that were crystallized with the SEC3-3B2 superantigen 
showed a conventional polyproline conformation up to P10 pocket on HLA-DR1, 
but GagP16 exhibits an additional unique beta hairpin loop at the C-terminus 
(Zavala-Ruiz et al., 2004b). A hairpin loop has not been observed in other MHC 
peptide structures. In structures of class II MHC with longer peptides, the N- and 
C-terminus of the peptide was observed to flank outside of the peptide binding 
groove (Madden, 1995; McFarland and Beeson, 2002). Additionally, there were 
interactions within GagP16 between the Leu at P8 and C-terminal residues, Thr 
at P13 and Ala at P12 (Zavala-Ruiz et al., 2004b). Understanding the 
determinants of the C-terminal hairpin loop of GagP16 and the contacts between 
TCR and HLA-DR1/GagP16 complex will give insight on why the C-terminal beta 
hairpin loop is necessary for T cell activation.  
Here, we study the determinants of the C-terminal hairpin loop of the 
GagP16 peptide in the binding site of HLA-DR1 by way of X-ray crystallographic 
analysis of complexes involving a variety of peptides consisting of partial 
segment of the GagP16 sequence. Our results suggest that the C-terminal 
hairpin determinants are not within the last seven residues of the peptide and 
suggest that the interactions between other parts of GagP16 and MHC may 
contribute to formation of the C-terminal hairpin loop that is essential for T cell 
response. In addition, we attempted to determine the crystal structure of the 
HLA-DR1/GagP16 and AC25 TCR complex where AC25 TCR is a T cell receptor 
cloned from cell lines raised against GagP16. 
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MATERIALS AND METHODS
 
HLA-DR1 expression, refolding and purification 
To get a large quantity of HLA-DR1 (DRA*0101, DRB1*0101) for 
crystallization, extracellular domains of HLA-DR1 subunits were overexpressed 
in E. coli and purified as inclusion bodies by anion exchange chromatography for 
refolding as previously described (Frayser et al., 1999). Briefly, both subunits 
were expressed separately as inclusion bodies from BL21(DE3) grown in LB 
medium and 100 mg/l ampicilin at 37°C. Bacterial cultures were induced at an 
OD600 of 1.0 by the addition of 1 mM isopropyl-ß-D-thio galactopyranoside 
(IPTG), and harvested 3 hours later. Cells were washed with 50 mM Tris-HCl 
pH 8.0 and lysed by resuspending the cell pellets in 50 mM Tris-HCl pH 8.0, 
1 mM MgCl2, 0.4 mg/mL DNase I, 0.4 mg/mL RNase A, 1 mg/mL lysozyme and 
brief sonication. Insoluble material was sedimented by centrifugation, and 
inclusion bodies were washed five times with 20 mM Tris–HCl pH 8.0, 23% (w/v) 
sucrose, 0.5% (v/v) Triton X-100, 1 mM EDTA and once with 20 mM Tris–HCl 
pH 8.0, 1 mM EDTA. Inclusion body pellets were resolubilized in 6 M urea, 
20 mM Tris-HCl pH 8.0, 2 mM EDTA and 5 mM dithiothreitol (DTT). The α 
subunit was purified through anion ion exchange, HQ, (Applied Biosystems) in 20 
mM Tris-HCl pH 8, 6 M Urea and 1 mM DTT then eluted with an NaCl gradient 
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from 0 to 1 M. The β subunit was purified in the same way but in a higher pH of 
8.5.  
The MHC subunits were together refolded by slowly adding the purified 
subunits in inclusion bodies into cold refolding buffer (100 mM Tris-HCl pH 8, 
2 mM EDTA, 0.3 mM oxidized glutathione, 0.3 mM reduced glutathione), at a final 
protein concentration of 16 mg/l α HLA-DR1 and 16 mg/l ß HLA-DR1, and 5x 
molar concentration of peptide before a 3 day incubation at 4°C. The refolding 
mix was then concentrated and buffer exchanged through ultrafiltration before 
purification through HQ anion exchange column (Applied Biosystem) in 20 mM 
Tris-HCl pH 8.0 with a linear gradient from 0 to 1 M NaCl. Next, the MHC peptide 
complex was purified further by size exclusion chromatography (Superdex  S200, 
Pharmacia Biotech) in phosphate buffered saline. 
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Superantigen, SEC3-3b2, expression and purification 
The super antigen, SEC3-3b2, was expressed in the periplasm of E. coli 
BL21(DE3) grown in 2xYT medium and 100 mg/l chloramphenicol at 27°C as 
previously described (Andersen et al., 1999).  Bacterial cultures were induced at 
an OD600 of 1.0 by the addition of 1 mM isopropyl-ß-D-thio galactopyranoside 
(IPTG), and harvested 5 hours later. Protein was extracted via osmotic stress in 
TES (0.2 M Tris, 0.5 mM EDTA, 20% sucrose) buffer followed by 0.2x TES buffer 
and purified through a Red A affinity column followed by anion exchange column 
(MonoQ, GE Healthcare).  
 
 
AC25 single chain TCR expression and purification 
AC 25 TCR α and β genes were isolated by Phillip Norris and Yuri Sykulev 
(unpublished data) and from the AC25 T cell (Norris et al., 2004) and were 
transferred to an E. coli periplasm expression system (Maynard et al., 2005) by 
Zarixia Zavala-Ruiz and Lawrence J. Stern. The TCR construct consist of the Vα 
and Vβ domains of AC25 TCR and linked through a (Gly4Ser)4 connecting the N-
terminus of the Vβ domain to the C-terminus of the Vα domain similar to that was 
in PDB 1U3H (Maynard 2005). The covalently bound α/β variable domain TCR, 
AC25scTCR, was expressed in the periplasm of E. coli BL21(DE3) grown in 
2xYT medium and 100 mg/l chloramphenicol at 27°C. Bacterial cultures were 
induced at an OD600 of 1.0 by the addition of 1 mM IPTG, and harvested 5 hours 
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later. Cells were pelleted and resuspended in TES buffer. Osmotic stress was 
induced by 0.2x TES buffer and the supernatant was purified through a Ni-NTA 
affinity column (Qiagen) in PBS and eluted with 30 mM imidazole. AC25scTCR 
was further purified by size exclusion column in PBS (Superdex S200, GE 
Healthcare).  
 
Circular dichroism and thermal melt 
AC25scTCR unfolding was monitored using a Jasco model J810 CD 
spectrophotometer in the range of 200-250 nm, 0.2 cm cell length and 2.5 nm 
bandwidth. AC25scTCR was in 10 mM Tris-HCl, pH 7.5 and 0.6 mg/mL. The 
temperature was increased from 6 to 70°C and CD measurements were 
recorded every 6 degrees.  
 
Peptide synthesis  
Peptides were synthesized using standard solid phase 
fluorenylmethoxycarbonyl (F-moc) chemistry (Symphony instrument, Protein 
Technology, Inc.), cleaved and deprotected. Crude peptides were precipitated in 
diethyl ether two times before lyophilization and then purified by reverse phase 
high-pressure liquid chromatography (Vydac-C18). Peptides were characterized 
by matrix- assisted laser desorption ionization time of flight, MALDI-TOF, mass 
spectrometry. To prevent ionization of the terminus, peptides were aminated at 
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the C-terminus. Concentrations were determined using the theoretical extinction 
coefficients.  
 
Surface plasmon resonance  
The binding experiments were done on a BIAcore3000 using CM-5 
carboxymethyldextran-coated gold chips coupled to modified avidin 
(Neutravidin). HLA-DR1 tetramers complexed with GagP16 or HA or A2-gag (Gift 
from Yuri Sykulev) was immobilized. AC25scTCR was injected at 2 mL/min at 67 
µM. Volumes were adjusted to 1 µL, 0.5 µL, and 0.25 µL to avoid nonspecific 
binding.  As a control, HLA-A2/gag peptide complex was immobilized and 
specific TCR-D3#1 was injected. 
 
Crystallization, structure determination and refinement 
Crystals were grown for X-ray diffraction experiments by vapor diffusion 
method in hanging drops at 4°C by combining 1 µL of protein (10 mg/mL) with 
1 µL of well solution (2% polyethylene glycol 4000, 10% ethylene glycol, 100 mM 
sodium acetate pH 5.4-5.6).  The protein solution consisted of equal molar 
concentration of HLA-DR1/peptide complex and SEC3-3b2. Crystals for data 
collection were approximated to be 100 µm x 100 µm x 50 µm in size. For data 
collection, crystals were first transferred into a cryo-protecting crystallization well 
solution with 25% ethylene glycol and then flash frozen in liquid nitrogen. X-ray 
diffraction data were collected under cryo conditions from single crystals 
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containing peptides PKYVKQNTLKLEGATP, PKYVKQNTLLLEGATP or 
PKYVKQNTLLSEGATP to 2.8, 2.2 and 2.2 Å resolution, respectively, at the 
National Synchrotron Light Source, beamline X29A, using 1.0898 Å wavelength 
X-rays. Oscillation images were processed with the program package HKL2000 
(Otwinowski, 1997). The structures of the complexes were determined by 
molecular replacement with the starting model of HLA-DR1/GagP16 in complex 
with the superantigen, SEC3-3b2, without GagP16 peptide (PDB 1SJH). Model 
building and rebuilding were done in O and COOT (Jones et al., 1991). Rigid 
body and positional refinement was performed in PHENIX (Adams et al., 2010). A 
bulk solvent correction and anisotropic B-factor tensor were applied throughout 
the refinement. Refinement statistics are as described in Table 4.1. 
AC25scTCR complexed with HLA-DR1 and GagP16 crystals were grown 
at 4°C by vapor diffusion method in hanging drops consisting of 1:1 volume ratio 
of protein solution and crystallization well solution. The protein solution consisted 
equal molar concentrations of AC25scTCR and HLA-DR1/GagP16 complex at 
14.5 mg/mL. The well solution consisted of 21% PEG 3350, 0.1 M Hepes, pH 7.5 
and 0.2 M LiSO4. Crystals were estimated to be smaller than 20 µm x 50 µm x 20 
µm and transferred into cryo condition consisting of well solution with the addition 
of 25% glycerol. X-ray diffraction data were collected from a single crystal at the 
National Synchrotron Light Source, beamline X6A, using 1.0 Å wavelength X-rays 
and ADSC Q270 CCD detector. Oscillation images were processed with the 
136
program package HKL2000 (Otwinowski, 1997). Molecular replacement method 
for phase estimation were conducted using Phaser (McCoy et al., 2007).  
 
RESULTS 
To investigate the determinants of the hairpin loop at the C-terminus of 
GagP16, the following designed peptides, which are hybrids between the HA 
peptide and GagP16 peptides, were used for crystallographic studies: (1) Hybrid 
1, PKYVKQNTLKLEGATP, is a peptide where the last 5 residues is of GagP16 
and the first 11 residues of HA, (2) Hybrid 3, PKYVKQNTLLLEGATP, is the same 
as hybrid 1 with the exception of a Leu at the P8 instead of a lysine because Leu 
at P8 in GagP16 appears to be involved in some interactions with Ala and Thr. 
(3) Hybrid 2, PKYVQNTLLSEGATP, is the last 7 residues of GagP16 and the first 
9 residues of HA, The crystal structures of each of the complexes were examined 
for presence of the hairpin loop at the C-terminus. The crystals were grown in the 
similar conditions as those of HLA-DR1 with GagP16 and SEC3-3b2 to facilitate 
crystallization. Crystals typically grew less than a week after drops were set up. 
The protein crystallized in the same space group, R3 and they yielded 
comparable resolution with the exception of hybrid 1. Initial maps were 
constructed without peptide in the binding groove and built in with confidence. 
Arp/Warp was utilized for hints of additional density in the C-terminal region 
(Cohen et al., 2004). Fo-Fo maps were generated using structure factors of HLA-
DR1/HA crystals to see differences in the C-terminal region.  
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Determinants of the GagP16 C-terminal hairpin turn 
The crystal structure of HLA-DR1 in complex with hybrid 1, 
PKYVKQNTLKLEGATP, was determined with the resolution of 2.8 Å. Electron 
density was observed for first 13 residues, PKYVKQNTLKLEG, of the hybrid 1 
peptide. It is not likely to have formed a loop that is not observable because the 
main chain of the last glycine residue points out of the peptide binding groove 
instead of pointing towards the binding groove to complete the hairpin turn as 
exhibited by GagP16 (Figure 4.1). The crystal structure of HLA-DR1 complexed 
with hybrid 1 peptide suggests that not only the last 5 residues of the GagP16 
peptide are responsible for the C-terminal hairpin turn needed for T cell 
activation. 
Hybrid 2 peptide, PKYVKQNTLLLEGATP, in complex with HLA-DR1 
diffracted to 2.2 Å. The electron density for this complex yields density for the 
peptide from the N-terminal proline to the P11 Gly. Similar to the previous 
structure of hybrid 1 peptide, Cα main chain of the Gly points away from the 
peptide binding groove  (Figure 4.2). This data suggest that not only the last 5 
residues of the GagP16 peptide but also P8 are important for interactions with 
the P12 Ala and P13 Thr on the other side of the turn does not dictate the C-
terminal hairpin turn needed for T cell activation. 
 To further study the determinants of the C-terminal hairpin loop we 
analyzed the crystal structure of HLA-DR1 in complex with peptide hybrid 3, 
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PKYVQNTLLSEGATP, which diffracted to 2.2 Å. This peptide consists of all four 
of the residues involved in the hairpin turn in GagP16 in addition to a Leu in the 
7th position. Electron density suggest that the loop does not form within these 
residues. Only electron density from the first residue to the Ser at P9, which is 
the first residue in the observed hairpin turn, was observed. This data shows that 
the last 7 residues alone does not dictate the hairpin turn. All the residues that 
appear to be involved in the hairpin turn and C-terminal structure within the 
peptide are conserved but it is still not sufficient in formation of the hairpin turn 
(Figure 4.3). These data suggest that the sequence of the residues directly 
involved in the secondary structure alone does not dictate the formation of the 
secondary structure observed in GagP16 in the context of HLA-DR1.  
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Figure 4.1. Electron Density of Hybrid 1 Peptide in Binding Groove.  
Top. Omit map density for peptide in peptide binding groove, hybrid 1 
(PKYVKQNTLKLEGATP) where underlined residues are same as those in 
GagP16 peptide. All atoms shown were omitted from model calculations.   
Bottom. Overlay of hybrid 1 peptide (carbon colored green) with GagP16 peptide 
(carbon colored magenta) and residues labeled according to their pocket 
numbers. Blue mesh represents |2Fo-Fc| electron density, sticks represent 
peptide model. PDB ID used is 1SJE. 
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Figure 4.2. Electron Density of Hybrid 2 Peptide in Binding Groove.  
Top. Omit map density for peptide in peptide binding groove, hybrid 2 
(PKYVKQNTLLLEGATP) where underlined residues are same as those in 
GagP16 peptide. All atoms shown were omitted from model calculations.   
Bottom. Overlay of hybrid 1 peptide (carbon colored green) with GagP16 peptide 
(carbon colored magenta) and residues labeled according to their pocket 
numbers. Blue mesh represents |2Fo-Fc| electron density, sticks represent 
peptide model. PDB ID used is 1SJE. 
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Figure 4.3. Electron Density of Hybrid 3 Peptide in Binding Groove.  
Top. Omit map density for peptide in peptide binding groove, hybrid 2 
(PKYVKQNTLLSEGATP) where underlined residues are same as those in 
GagP16 peptide. All atoms shown were omitted from model calculations.   
Bottom. Overlay of hybrid 1 peptide (carbon colored green) with GagP16 peptide 
(carbon colored magenta) and residues labeled according to their pocket 
numbers. Blue mesh represents |2Fo-Fc| electron density, sticks represent 
peptide model. PDB ID used is 1SJE. 
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Studies with AC25 T cell receptor 
 To visualize the interaction between the TCR and HLA-DR1 in complex 
with GagP16, we expressed the variable domains of the AC25 TCR covalently 
bound by a linker, (Gly4Ser)4, termed AC25scTCR. Purified AC25scTCR eluted 
from size exclusion chromatography as a single monomer (Figure 4.5). Circular 
dichroism and thermal denaturation suggest a melting temperature at 59°C 
(Figure 4.6). No binding between AC25scTCR and HLA-DR1/GagP16 was 
detected in surface plasmon resonance (SPR) experiments (Figure 4.7). A 
possible reason for this result can be due to the expected weak interaction 
between α/β TCR and class II MHC (Kd 10-5 to 10-7 M) and hence be difficult to 
detect (Cole DK, 2007). Binding of HLA-DR1/GagP16 tetramers to AC25 
expressing T cells was observed in staining experiments (Norris et al., 2006).  
Since the T cell activation ED50 values of cells expressing AC25 compared to 
cells expressing HA1.7 TCR are to the same order of magnitude (~1 mM), the 
concentration dependence for MHC tetramer staining of the two TCRs are 
similar, and these properties have been linked to the intrinsic MHC/TCR affinity; it 
is expected that the AC25TCR is likely to bind with the similar affinity as HA.1.7 
TCR with Kd ~30-6 M (Cochran et al., 2000; Falta et al., 2005; Norris et al., 2004; 
Stone et al., 2001; Zavala-Ruiz et al., 2004b). Binding of recombinant soluble 
TCR and immobilized biotinylated MHC-peptide complex have been detected to 
Kd values of 250-6 M using SPR (Huseby, E and Stern, L.J. personal 
communications). Another possible reason for the lack of binding observation 
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can be due to the clones derived from HIV patients expressing AC25 TCR. The 
cells can express two Vα strands and this particular Vα does not recognize HLA-
DR1/GagP16 (Padovan E, 1995). We crystallized the protein solution consisting 
of a 1:1 molar ratio of HLA-DR1/GagP16 complex to AC25scTCR. Crystals 
smaller than 40 µm x 40 µm x 40 µm grew and diffracted to 5 Å. Though low 
resolution, the overall mode of interaction between the MHC and TCR can be 
visualized. Using PHASER, molecular replacement using the TCR HA1.7 in 
complex with HLA-DR1/HA peptide was conducted and no solution were found 
(Cohen et al., 2004). Matthews coefficient analysis suggest that 2 MHC/TCR 
complex can be in the crystal with 58% solvent (Matthews, 1968). No solutions 
were found when searching for both TCR and MHC as their own entity. When 
searching for a solution with only HLA-DR1, a solution was found with 3 
molecules in the asymmetric unit with solution scoring TFZ=9.6, LLG=82, 
TFZ=24.9, LLG=383, RFZ=3.0 ,TFZ=21.0 ,LLG=726 and LLG=1734. The MHC 
molecules of the solution leaves little space for TCR packing and electron density 
maps yielded little or no density for regions other than in those which were 
modeled for HLA-DR1 (Figure 4.7). The crystals may have been of HLA-
DR1/GagP16 alone. 
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Figure 4.4. AC25 Single Chain TCR Purifies as a Monomer.  
Top. Size exclusion chromatograph of AC25scTCR shows single eluted peak. 
Molecular weight standards are marked above curve.  Bottom left. Analysis of 
AC25scTCR stained by coomassie blue on 10% SDS PAGE in non-reducing 
conditions shows a single band. Bottom right. The native gel showing 
AC25scTCR in a single band. 
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Figure 4.5. Thermal Melt of AC25 Single Chain TCR Observed by Circular 
Dichroism. 
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Figure 4.6. Surface Plasmon Resonance Does Not Detect Interaction 
Between AC25scTCR and HLA-DR1/GagP16. Red trace indicates positive 
control between HLA-A2/gag peptide and D3#1 TCR. The blue trace is 
observation of the HLA-DR1/GagP16 peptide immobilized with AC25scTCR 
injected. Black line was the same as blue but with HLA-DR1/HA peptide 
immobilized. 
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Figure 4.7. Crystal Packing of HLA-DR1/GagP16. The three molecules of HLA-
DR1 found in the molecular solution shown in blue, green and yellow and the 
symmetry related molecules are in pink. 
154
DISCUSSION 
The C-terminal loop exhibited by GagP16 in context of HLA-DR1 is also 
exhibited in the context of the N-terminal domain of the mature HIV-1 capsid 
protein. The N-terminal region of the peptide exhibits a helix in the protein and in 
HLA-DR1, this conformation is enforced though main chain interactions to hold a 
type II polyproline conformation. One possible explanation for the weak electron 
density for C-terminal hairpin observation is due to limitation of the X-ray data at 
these resolutions though the resolution of the data sets collected was 
comparable to the GagP16 crystal structure data, with the exception of hybrid 
one peptide. The lack of density at C-terminal hairpin turn when the N-terminal 
region was replaced by the HA peptide suggests that the binding of peptide into 
the peptide binding groove may promote the formation of the secondary structure 
outside the binding groove. Peptide alanine scanning experiments suggest that 
the P13 Thr is critical for T cell response but not for MHC binding. This hairpin 
turn may place the P13 Thr in the appropriate position for T cell activation. The 
hairpin formation can be determined not only by the sequence involved in the 
turn but also by the residues that bind into the MHC. One possible explanation 
for this is that upon binding into the MHC peptide binding groove anchoring 
residues holding the peptide down positioning the C-terminus in a conformation 
for hairpin turn formation. In the peptides with the HA N-terminal region, the 
peptide binds into the grooves differently because of different anchoring residues 
and does not set up the appropriate conditions for the hairpin turn to occur. For 
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example, the structure with the peptide consisting of only the last five residues of 
GagP16 exhibited a peptide in the binding groove that is less puckered than the 
GagP16 peptide in the binding groove. Can it be that the residues at P1, P4, P7 
and P9 are holding the hybrid peptide in a way that prevents the formation of the 
beta hairpin turn? The P9 Leu replaces the GagP16 Ser at P9. Possibly, 
interactions in the pocket hold the peptide down into the groove and not allowing 
for the correct angle between the first and second residues of the turn to form. 
These data suggest that the manner in which a peptide binds into the groove and 
not the sequence alone dictates a T cell response. 
 The mode of interactions between AC25 and HLA-DR1/GagP16 was not 
visualized in crystallographic studies. Molecular modeling of HA1.7 TCR onto 
HLA-DR1/GagP16 suggests that there can be interactions between the last two 
residues of the peptide with the CDR1 and CDR3 loops of the Vα chain. 
However, the structure of GagP16 does not have the last proline residue that 
could prevent this kind of interaction. The crystal structure of the trimeric complex 
can confirm the mode of interaction and increase our library of class II MHC / 
TCR interaction motif. The possibility of cloning out the incorrect AC25 TCR is 
likely because it was not observed in the co-crystallizations and SPR binding was 
not detected even though expected weaker MHC/TCR affinities of other 
complexes were observed using SPR. In that case, cloning out another TCR 
from the TCR clones is necessary to further study the interaction between AC25 
TCR and HLA-DR1/GagP16 hairpin loop. Cloning out another TCR from the cell 
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lines specific for GagP16 can be difficult due to the fragility of the cells and 
difficulty of revitalizing the cells for our purpose. If we do get another TCR cloned 
out from the AC25 cell line, one possible way to ensure MHC and TCR 
interaction is by tethering of the peptide to the TCR through a flexible peptide 
cross linker. Previous crystal structures of TCR/MHC have linked the peptide 
through the C-terminus of the peptide and the N-terminus of the TCR (Hennecke 
and Wiley, 2002).  Since the interaction of interest in the C-terminus of the 
peptide, the linkage will need to be through the N-terminus of the peptide. The 
studies discussed in this chapter provide insight on the nature of determinants for 
the C-terminal hairpin observed so far only in the context of the GagP16 peptide 
in HLA-DR1 but not in other peptides that have all the components of the loop.  
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Table 4.1. Data Collection and Refinement Statistics for  
DR1/hybrid Peptides 
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Table 4.2.  Data Collection Statistics for AC25scTCR with DR1/GagP16 
 
 
 HLA-DR1/ GagP16 
AC25scTCR 
Data collection 
Space group I4122 
Cell dimensions 
    a, b, c (Å) a=b=125.4 
c=440.3 
    α, β, γ  (°)  90, 90, 90 
Resolution (Å) 50-5 
Rsym or Rmerge 28(56) 
I / σI 5(1.6) 
Completeness (%) 91(70) 
Redundancy 6.2(5.7) 
*Highest-resolution shell is shown in parentheses.  
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CHAPTER 5 
Conclusions and Future Directions 
 
The purpose of my studies was to enhance our structural and functional 
understanding of the molecules involved in antigen presentation. In Chapter 2, I 
described the structural characterization the ER aminopeptidase, ERAP1 for the 
first time with insights on how peptides can bind into the peptide binding cavity 
formed by the catalytic domain II and the helical C-terminal domain IV. In 
Chapter 3, the (4-DAPA)-HA peptide was characterized in the context of HLA-
DR1 to show that it can be used in class II MHC antigen processing studies. 
Chapter 4 provided insights on the determinants of the unique C-terminal hairpin 
loop exhibited by an HIV gag derived peptide in complex with class II MHC.  
 
Mechanism for Activation of ERAP1 
The structure of ERAP1 provides a first glance of this aminopeptidase and 
the 8th protein represented in the M1 family of metallopeptidases. This structure 
supports the idea that even though M1 aminopeptidase family members exhibit 
low sequence identity, they exhibit structural homology. Though the M1 
aminopeptidases were categorized because of their thermolysin like fold and 
conserved HExxEx18H and GXMEN motif and they appear to share structural 
homology at the N-terminal domain and in the C-terminal domain (Addlagatta et 
al., 2006; Bauvois et al., 2008; Fournie-Zaluski et al., 2009; Goettig et al., 2005; 
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Haeggstrom, 2000; Holland et al., 1992; Ito et al., 2006; Tholander et al., 2008; 
Thunnissen et al., 2001). We have identified Tyr438 as an important residue for 
activity suggesting that ERAP1 can be in an inactive open conformation.  The 
differences between molecules of the asymmetric unit and normal mode analysis 
suggest an opening and closing motion between the catalytic domain II and the 
helical domain IV. In addition, another structure of ERAP1, which was deposited 
while our manuscript, was in preparation shown an even more closed form than 
our analysis. ERAP1 is the first M1 aminopeptidase to exhibit two conformations 
in crystal structures. Our studies support a mechanistic model where peptide 
binding occurs in the open conformation with interactions in the large cavity 
between the peptide substrate or activators and the C-terminal domain residues 
of ERAP1. A conformational change can then occur where the C-terminal domain 
comes into closer proximity with the catalytic domain and as a result of that, H5 
rotates placing Tyr438 into a position for substrate hydrolysis. More analysis will 
be needed to determine the exact interactions between peptide substrate and the 
activation sites of ERAP1. 
 
ERAP1 and ERAP2 molecular interactions 
The work in Chapter 2 explains the N-terminal substrate preference 
differences in ERAP1 and ERAP2. ERAP1 and ERAP2 activity differs in 
substrate peptide N-terminal residues preferences. ERAP1 prefers hydrophobic 
residues and ERAP2 prefers basic residues in the N-terminal position (Hattori et 
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al., 1999; Tanioka et al., 2003). Since the two aminopeptidases are more than 
50% homologous, the structure of ERAP1 provides a better model for ERAP2 
than other M1 aminopeptidases. Molecular modeling of residues in the S1 site 
explains the difference in substrate preference in ERAP1 and ERAP2. ERAP1 
has residue Gln181 in place of residue Asp198 in ERAP2. Asp198 in ERAP2 
allows for charged residues such as Arg and Lys to bind into the pocket where as 
Gln181 in ERAP1 allows for smaller uncharged residues. Additionally, Gln 181 
may play a structural role in the active site because mutation studies show that a 
Gln to Ala at position 181 result in loss of aminopeptidase activity (Goto et al., 
2008). Both structures of ERAP1 show Gln181 is in a position to interact with the 
conserved GAMEN motif near the active site and can be important in holding the 
GAMEN loop in place for activity.  
 Our studies provide a possible model for ERAP1 and ERAP2 interactions. 
ERAP1 has been shown to interact with ERAP2 in co-immunoprecipitation and 
sucrose density gradient centrifugation studies (Saveanu et al., 2005). The 
concerted activity of the two enzymes allow for efficient processing of a peptide 
found in HLA-B27 HIV infected patients (Saveanu et al., 2005). The epitope 
precursor peptide consists of hydrophobic and positively charged N-terminal 
residues. About 10% of ERAP1 and 20% of ERAP2 were suggested to be in a 
complex; this raises the question of the importance of this interaction (Saveanu 
et al., 2005). The interaction between ERAP1 and ERAP2 can result in ERAP1 
inhibition, activation and can be a mechanism for ER retention. Although, the 
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asymmetric unit of ERAP1 in the open conformation consists of three molecules, 
a homotrimer has not been observed in gel filtration studies or dynamic light 
scattering studies. The interactions between the molecules in the asymmetric unit 
involve residues in domains I and III. Domain III forms a hinge between the 
catalytic domain II and the C-terminal domain IV that makes the peptide binding 
cavity. Conformational changes in domain III can translate to domain II and IV 
opening and closing. Since ERAP1 and ERAP2 are homologous proteins with 
~50% identity and more than 75% homology, the interactions between the 
molecules within the asymmetric unit can be used to predict the mode of 
interactions between ERAP1 and ERAP2. Further exploration of the interactions 
between ERAP1 and ERAP2 and enzymatic studies of the two enzymes can 
provide an understanding of the significance of the partnership. 
 
Conformational change in ERAP1 
In the studies described in Chapter 2, ERAP1 shows an open 
conformation that is likely to be inactive because Tyr438 faces away from the 
other catalytic residues. Does this open conformation allow for longer products to 
escape before further N-terminal residue cleavage? Since the open conformation 
was crystallized with the presence of the aminopeptidase inhibitor, bestatin, it is 
possible but unlikely that ERAP1 exhibits this conformation without an inhibitor. 
The introduction of bestatin is unlikely to force Tyr438 to point away from the 
active site because structures of other M1 aminopeptidases, LTA4H and pepN, 
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with and without bestatin have shown no changes in this residue (Addlagatta et 
al., 2006; Parnas et al., 1996). Further exploration of the ERAP1 conformations 
can explain their role in substrate binding and unique product formation. 
Additionally, there may be a conformation dependency for ERAP1 interaction. 
Understanding the role of conformational changes may lead to identification 
binding partners and catalytic mechanism. 
 
Other oxytocinase subfamily members of M1 aminopeptidase 
ERAP1 together with ERAP2 and IRAP forms the oxytocinase subfamily 
of aminopeptidase. ERAP1 and IRAP were shown to trim N-extended SIINFEKL 
to different lengths. ERAP1 trims LSIINFEKL to SIINFEKL and IRAP trims 
LSIINFEKL to IINFEKL and INFEKL (Georgiadou et al., 2010). The structure of 
IRAP in comparison with the structures of ERAP1 can provide an explanation of 
how ERAP1 can stop aminopeptidase activity at 8 or 9 residues long whereas 
IRAP can cleave down to 6 or 7 residues long. Does IRAP or ERAP2 exhibit an 
open and closed conformation to the same extent as ERAP1? Further 
exploration of closely homologous family members can provide a better 
understanding of the importance of conformational changes for enzymatic 
activity.  
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Class II MHC antigen presentation studies 
The studies in Chapter 3 show that the fluorogenic peptide, (4-DAPA)-HA, 
binds to HLA-DR1 in the same register and with the same affinity as to native HA 
peptide. It also activates HA specific T cells, HA1.7, similarly as compared native 
HA. This environmentally sensitive peptide is suitable for use in cellular studies 
that can shed light on unclear aspects of class II MHC antigen processing. For 
instance, it remains unclear on when the interactions of HLA-DM and HLA-DO 
with HLA-DR1 occur. Does HLA-DO inhibit the loading of peptides assisted by 
HLA-DM by binding to HLA-DR1 forming a tertiary complex? How are the 
antigens spatially controlled in the endosomes? Further analysis of peptide 
loading in vivo can enhance our understanding of the antigen loading processes 
that occurs in the endosomes. Since these probes provide a direct measurement 
of peptide binding into MHCs and are insensitive to pH and can be used in any 
cell type, they can be used to study HLA-DM and HLA-DO peptide binding 
regulation or antigen differential compartmentalization in the endosomes. Studies 
of weakly to strongly binding peptide labeled with these probes can show real 
time compartmental regulation of peptides and the roles of HLA-DM and HLA-DO 
in peptides with different affinities to class II MHC.   
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Class II MHC, peptide and TCR modes of interaction 
Our studies in Chapter 4 suggest that N-terminal residues of the gag 
derived peptide effect the formation of the C-terminal hairpin loop in the context 
of HLA-DR1. These studies suggest that primary sequence alone is not enough 
to predict T cell activation in residues flanking the peptide binding groove. 
Currently, there are 12 structures of class II MHC, peptide and α/β TCR 
complexes in the protein database. About half of the complexes display the 
conventional diagonal mode of binding where the TCR CDR loops predominantly 
interact with the center of the peptide binding groove and the residue 
corresponding to the P7 pocket displayed by TCR HA.1.7 to HLA-DR1/HA 
peptide (Hennecke and Wiley, 2002). The other complexes display a mode of 
binding where the TCR CDR loops display a peptide N-terminus bias binding 
motif as in the TCR Ob.1A12-HLA-DR2-myelin basic protein derived peptide 
(Maynard et al., 2005). Modeling HLA-DR1/ GagP16 into the conformations 
suggest that it is likely to bind either in the conventional diagonal binding 
conformation where additional interactions between the C-terminal residues and 
the Vβ1 and Vβ3 CDR loop can be achieved with the GagP16 but not with 
GagP13. Since binding of the N-terminal residues to HLA-DR1 affects the 
formation of the loop, the question arises of whether it is the hairpin loop or the 
residue sequence that is important for T cell recognition. Though alanine scans 
of the C-terminal residues were done suggesting that the residues in that region 
are important for T cell recognition, it does not differentiate between whether the 
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loop or the sequence is important for T cell activation. The trimeric crystal 
structure of HLA-DR1/GagP16 with AC25 TCR could reveal how this mode of 
interaction with the last five residues of GagP16 are important for a T cell 
response. It will be interesting to observe different modes of interaction between 
the GagP13 with TCR and GagP16 with TCR that can differentiate between T 
cell activation and T cell binding.  
 
Future Studies in Antigen Processing 
The work described in this thesis provides insights for further studies to 
better understand antigen processing. The structural characterization of ERAP1 
provides the basis for further exploration to understand why polymorphisms 
observed in patients with ankylosing spondylitis can affect the antigen 
presentation that can affect T cell responses. The ERAP1 structure also the 
basis for substrate design to understand the substrate length specificity of 
ERAP1 that can be applied to the understanding of the mechanism of the other 
M1 aminopeptidase family members. Further studies on the ERAP1 peptide 
binding site and binding partners can help understand ERAP1’s effect in 
conditions such as cancer, diabetes, hypertension and ankylosing spondylitis 
and explore the possibility of ERAP1 as a therapeutic drug target. The structural 
characterization of (4-DAPA)-HA in complex with HLA-DR1 provides 
groundwork for further studies using (4-DAPA)-HA as a reagent for studying in 
real time and allowing visualization of peptide binding in a cell. The studies 
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involving the GagP16 peptides suggested the C-terminal loop does not depend 
solely on the sequence and factors other than sequence can contribute to the 
formation of the loop and therefore eliciting a T cell response. Further studies 
are necessary to understand other determinants of the GagP16 C-terminal loop 
and how it interacts with TCR. Future studies involving ERAP1, (4-DAPA)-HA 
peptide, and GagP16 will provide an increase in understanding of antigen 
presentation, processing and autoimmunity that can lead to potential drug 
development and targets.  
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A.1. IRAP Crystallization and Data Collection 
Crystallization trails were executed using recombinant soluble IRAP 
(without the transmembrane domain) using protein that was provided by the 
laboratory of Peter van Endert. IRAP was treated with carboxypeptidase A to 
cleave C-terminal ends and gel purified using Superdex S200 is PBS. Protein 
was concentrated to 10 mg/mL concentration in 10 mM Tris-HCl buffer, pH 7.5. 
Small crystal plates (100 µm x 40 µm x ~5 µm) formed after ten days of 
incubation at 4°C in hanging drops. Well solution consisted of 0.1 M Tris-HCl, pH 
8.0, 18% PEG 8K, and 1 mM glutathione with the ratio of 10:1 oxidized to 
reduced form. Crystals were frozen in 30% 2-methyl-2,4-pentanediol and 1 of 10 
crystals shot diffracted beyond 3 Å. X-ray diffraction data were collected as 1° 
oscillations at 100 K with 1 Å radiation at beamline, 14-ID-B, at the Advance 
Photon Source. Data were processed and scaled using HKL2000 (Otwinowski, 
1997). Data collection statics is shown in table below. Matthews coefficient 
analysis estimates 6 molecules in the asymmetric unit (Matthews, 1968). 
Molecular replacement was tried with side chain truncated ERAP1 (PDB 3MDJ) 
as the search model using MolRep (Vagin et al., 2004). Since ERAP1 crystallized 
with 3 molecules in the asymmetric unit, we tried the trimer and the monomer as 
search models. Lock rotation function analysis suggests that it has a three fold in 
the asymmetric unit. Only searches with monomers yielded a solution (contrast= 
3.6, Rfactor= 0.578), which did not appear to be correct because the composite 
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omit map calculated from this solution was not interpretable. Experimental 
phasing will be needed for structure determination.  
 
 
 
 
 IRAP 
Data collection  
Space group C2 
Cell dimensions  
    a, b, c (Å) 204.4, 147.2, 207.2 
    α, β, γ  (°)  90, 93.3, 90 
Resolution (Å) 43-3 (3.2-3)* 
Rsym (%) 33 (58) 
I / σI 2.7 (1.1) 
Completeness (%) 97 (85.8) 
Redundancy 1.9 (1.5) 
* Highest resolution shell 
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A.2. Hydrodynamic Studies of ERAP1  
 
To study conformational changes in ERAP1, dynamic light scattering 
experiments were conducted in the presence of L-AMC activator, SIINFEKL. The 
results suggest that the noise within the experimental set up is as much as the 
variation in hydrodynamic radius. There appears not to be a concentration 
dependence of hydrodynamic radius or sample homogeneity change according 
to DLS. The difference in radius of gyration between open and closed forms of 
ERAP1 is about 2 Å, which is less than the variation between the readings.  
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A.3. Studies of ERAP1 L-AMC Hydrolysis  
 
Proteins from preps that have higher specific activity tend to produce ERAP1 
crystals. Not all preps yielded crystals. To increase signal to noise ratio in our 
enzymatic assay for ERAP1, we studied the effect of glutathione and NaCl on the 
assay. To study the effect of reducing environment on ERAP1 L-AMC activity, 
ERAP1 activity with reaction buffer consisting of 10:1, 1:1, 1:10 ratio of oxidized 
to reduced glutathione. Total concentration of glutathione was 1 mM. Though it is 
not clear whether oxidizing glutathione or reducing glutathione conditions were 
more favorable for L-AMC hydrolysis, it was clear that 1 mM glutathione 
increased the activity of ERAP1.  
ERAP1 appears to have a concentration dependence decrease of activity 
by NaCl. The original reaction buffer consisted of 100 mM NaCl which is only 
~30% of what the activity could have been without any NaCl. These experiment 
suggest that the addition of 1 mM glutathione and elimination of NaCl can 
increase the signal to noise of the L-AMC hydrolysis assay. 
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A.4. Circular Dichroism Analysis of ERAP1 
 
The secondary structure of ERAP1 was examined using circular dichroism. 
Samples of ERAP1 at 1.5 µM in 5 mM NaPi pH 7.5 spectra was obtained with a 
Jasco model J810 CD spectrophotometer between 195-250 nm using a 0.2 cm 
CD cell and 2.5 nm bandwidth. Data suggest that there is little if any secondary 
structural change due to temperature differences. The 222 nm point indicative of 
helical content seems to have increased slightly at 20°C. 
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A.5. ERAP1 Studies with Mass Spectrometry to Identify Glycosylation Sites 
and Disulfide Bonds 
To study the glycosylation sites and disulfide bonding pattern in ERAP1, ERAP1 
was submitted for mass spectrometry analysis (Proteomic Mass Spectrometry 
Lab, UMASS Medical School). Samples of Endo F treated and not treated 
ERAP1 were examined to determine glycosylation sites.  To determine disulfide 
bonds, ERAP1 was alkylated with iodoacetamide, reduced with dithiothreitol and 
modified with methyl methanethiosulfonate. Samples were digested with trypsin 
and pepsin before mass spectrometry analysis.  
 
Sequenced highlighted in red were observed in mass spectrometry analysis. 
Bold residues are modified residues. 
Analysis observed N-linked sugars at residues Asn 69, 154, 414, and Cys 193, 
404, 486 and 806 are involved in disulfide bonds.
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A.6. ERAP1 Trimer Packing in the Unit Cell. 
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A.7. ERAP1 Expression in Hi5 cells and Purification 
Modified from protocol by Efstratios Stratikos 
 
Outline:  
 
Express ERAP1 in Hi5 cells, concentrate and buffer exchange in concentrator, 
Purify with NiNTA, Concentrate for size exclusion purification, size exclusion 
purification, buffer exchange for ion exchange and purify in anion exchange 
Avoid freeze thaw process, aminopeptidase inhibitors and chelators. 
 
ERAP1 expression: 
 
1) Hi5 cells growth in serum free Excell 405 medium with 
antibiotic/antimycotic at 27°C. 
2) Cells are split one day before infection. 
3) Infect Hi5 cells at 0.5 million cells for 72 hrs at 27°C in shaker flask. Other 
flasks tend to cause cell death during infection. Test virus to cell ratio to 
determine optimal amount of virus to infect with. 
4) Harvest by centrifugation at 4000 x g for 20 minutes. ERAP1 will be in the 
supernatant. 
5) Concentrate supernatant and change buffer of supernatant by diluting 
concentrated protein by 10 fold and reconcentrate (1 L to 100 mL) in 4°C 
- Used spiral concentration system with 30 kDa MWCO 
- Exchange buffer to binding buffer 
o 50 mM Sodium Phosphate pH 8.0, 300 mM NaCl, 5 mM 
imidazole 
6) Filter concentrated ERAP1 through 0.45 µm filter. 
7) Bind supernatant to pre-equilibrated (same buffer) NiNTA resin (Qiagen) 
overnight in 4°C 
 
NiNTA purification: 
 
1) Wash column with 5 CV of starting buffer (50 mM NaP pH 8.0, 300 mM 
NaCl, 5 mM imidazole) 
2) First elution step with 5 CV (50 mM NaP pH 8.0, 300 mM NaCl, 15 mM 
imidazole) 
3) Second elution step with 5 CV (50 mM NaP pH 8.0, 300 mM NaCl, 30 mM 
imidazole) 
4) Third elution step with 5 CV (50 mM NaP pH 8.0, 300 mM NaCl, 100 mM 
imidazole) 
5) Check protein all elution and flow through for ERAP either by L-AMC or 
western or SDS PAGE.  
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For crystallography, ERAP1 is concentrated to 1 mg/mL and buffer exchanged to 
PBS for cleavage by carboxypeptidase A (Sigma) overnight (1:1 molar ratio) at 
room temperature. 
 
Size Exclusion Chromatography:  
 
Use Superdex S200 (GE Healthcare) column and PBS as the running buffer. 
Major peak is ERAP1 which elutes around 100 kDa according to standards. 
Buffer exchange pooled fractions by dialysis against 20 mM Tris-HCl pH 7.5 for 
anion exchange chromatography. 
 
Anion Exchange Chromatography: 
 
Using MonoQ column with starting buffer as 20 mM Tris pH 7.5 and elution buffer 
as 20 mM Tris-HCl pH 7.5, 1 M NaCl. The gradient is over 10 CV. There are 
usually multiple peaks (2 major peaks). All peaks are ERAP1 with comparable 
specific activity.  
 
Average yield for this prep and purification scheme is about 0.5 mg/mL with the 
carboxypeptidase A treatment and 1 mg/mL without carboxypeptidase A 
treatment. 
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A.8. Fluorometric L-AMC Assay for Aminopeptidase Activity 
Modified from protocol by Efstratios Stratikos 
 
Substrate: L-AMC (Bachem) 
Stock 50mM in DMSO, store at -20°C 
ERAP1 stock is 0.09 mg/mL in 10 mM Tris pH 7.5, 100 mM NaCl (stored at 4°C) 
Better activity observed at pH 8 (Optimum pH for ERAP1)  
 
Dilute substrate 500x to a final concentration of 100 µM in reaction buffer.  
(20 mM Tris pH 8, 100 mM NaCl buffer) 
 
Before reading with microplate reader, add 5 µl of ERAP1 to each well. 
Add 95 µL of 100 µM Leu-AMC right before reading. (This can be adjusted in 
reactions in which we do not want to dilute the samples). 
Measure using by exciting at 380 nm measure emissions at 460 nm. 
Set gain using well where you expect highest read out.  
 
Initial activity is the slope of the curve (of early linear part).  
You can calibrate the activity using aminomethylcoumarin (AMC) as a standard 
(so that the activity is product released per time unit) but this is generally not 
needed, just compare activity between different samples for purification 
purposes. Use at least 10 ng of ERAP1.  
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A.9. Expression of HLA-DR1 in E. Coli (Fermentation) 
Developed Mia Rushe 
 
Procedure: 
Day 1: 
1) Streak an LB-amp plate in the evening with BL21 cells of interest from 
frozen stocks. Incubate at 37°C overnight. 
Day 2: 
1) Put streaked plate at 4°C in morning, sealed with parafilm. 
2) Autoclave assembled fermentor filled with 10 L of 1 x LB broth, 1 L of 
distilled H2O, 1 L of 1 x LB broth, at least 150 mL 20% glucose, and 3-125 
mL Erlenmeyer flasks. 
3) In the early evening, add 83 mL sterilized LB broth to one of the sterile 
flasks. Add 83 mL Ampicillin (50 mg/mL) and 1.2 mL 20% glucose.  **If 
the cells are kanamycin resistant, substitute 83 mL of a 50 mg/mL stock 
of kanamycin sulfate for ampicillin. If cells are pLyss, add 83 mL 
chloramphenicol (35 mg/mL).**  
4) Mix well and take a 1 mL blank sample for OD600 measurements.  You 
may want to add 1 mL 20% NaN3 to prevent growth in the blank sample.  
Keep this blank in a plastic cuvette. 
5) The remaining LB solution will be split into different containers. Pipet 2 mL 
into a sterile 15 mL conical tube, 20 mL into a 50 mL conical tube, and 20 
mL into each of the remaining sterile Erlenmeyer flasks. Label the flasks 
1, 2 and 3. 
6) Pick one colony from your plate. Add it to your 15 mL tube and vortex 
vigorously. Take 200 mL of that tube and add it to the 50 mL conical tube 
and vortex vigorously. Take 200 mL of that tube and add it to Erlenmeyer 
flask #1 and swirl a lot. Take 200 mL from that flask and add it to 
Erlenmeyer flask #2 and swirl a lot. Take 200 mL of that flask and add it 
to Erlenmeyer flask #3. 
7) Grow the 3 Erlenmeyer flasks on a shaker table at 37°C overnight. 
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Day 3: 
1) Measure the absorbance at 600nm of each flask compared to the blank you 
saved.  Pick the one that is less than 1.0 OD600, but still has measurable 
growth in it. (0.7 is about ideal.) 
2) Set up the fermentor:  Add 10 mL of Ampicillin, 50 mg/mL, 100 mL 20% 
glucose (sterile), and 200 mL antifoam A.  **If the cells are kanamycin 
resistant, substitute 10 mL of a 50 mg/mL stock of kanamycin sulfate for 
ampicillin. If the cells are pLyss, also add 10 mL 35 mg/mL 
chloramphenicol.**  Mix well.  Remove 1 mL as a blank and store in a 
plastic cuvette, possibly with 1 mL 20% NaN3. 
3) Run the mixer on the fermentor at ~700 rpm, and run the air at 15 psi and 5 
LPM.  Watch for excessive foaming and add antifoam if it is necessary.  **If 
you have never set the fermentor up before, ask for help!! 
4) Seed the fermentor with 10 mL of the overnight flask you selected. 
5) Take samples and check the OD600 every hour until you get close to 1.0, 
and then check more frequently.  Do not overgrow! 
6) When the OD600 reaches 1.0, take a 1 mL sample “not induced.”  Spin 
down and re-suspend in 1x urea-SDS loading buffer. Freeze at -20°C. 
7) Add IPTG to 0.75 mM final concentration.  I use 10 mL of 0.75M IPTG 
stock (1000 x).  Allow to grow for 2-5 hours with IPTG.  
8) Take a 1 mL sample “induced.”  Spin down and re-suspend in 1x urea-SDS 
loading buffer.  Freeze at -20°C until you are ready to check the “not 
induced” and “induced” samples on a gel by SDS-PAGE. 
9) Spin down all the cells at 8000 x g and discard the supernatant.  For 
inclusion bodies, you may freeze the pellet at -20°C, or proceed with the 
inclusion body prep through the DNAse step and freeze at -20°C. 
 
To run the 12.5% SDS-gel: 
Take the 1 mL uninduced/induced bacterial pellets and resuspend in 40 µL of 
water.  Add 10 µL 5X Reduced SDS loading buffer with 6 M urea. Boil for 2 
minutes and spin down lysed cells. Load 10 µl of both samples onto the gel. Look 
for an induced band around 25 kDa. 
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A.10. Isolation of Class II MHC Subunits from Bacterial Pellets 
Modified protocol that was developed by Mia Rushe 
 
Solutions: 
DNAse solution (can be made and stored in freezer) 
 75 mM NaCl 
 50% glycerol 
 2 mg/mL DNAse (Sigma D-5025) 
Sucrose Solution (if no DTT can be stored on bench; same for following three 
solutions) 
 50 mM Tris-HCl, pH 8.0 
 25% sucrose 
 1 mM EDTA 
 0.1% NaN3 
 10 mM DTT (add just before use) 
Deoxycholate/Triton 
 1% Na Deoxycholate 
 1% Triton x100 
 20 mM Tris-HCl, pH 7.5 
 100 mM NaCl 
 0.1% NaN3 
 10 mM DTT (add just before use) 
Triton Solution 
 0.5% Triton x100 
 50 mM Tris-HCl, pH 8.0 
 100 mM NaCl 
 1 mM EDTA 
 0.1% NaN3 
 1 mM DTT (add just before use) 
Tris Solution 
 50 mM Tris-HCl  pH 8.0 
 1 mM EDTA 
 0.1% NaN3 
 1 mM DTT (add just before use) 
Urea Solution (make up fresh each time) 
 8 M urea 
 20 mM Tris-HCl, pH 8.0 
0.5 mM EDTA 
 30 mM DTT  
4 M MgCl2 
0.5 M EDTA pH 8.0 
*Protocol for pellet of 10 liter fermentor culture 
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Procedure (for pellet from 10 L culture): 
 
1. Spin down cells at 5000 x g and collect supernatant into a container, 
sterilize with 1% Wescodyne for 10-20 minutes, and then dump down the 
sink. 
 
2. With a rubber spatula, re-suspend fresh bacteria into a single plastic 
container with ~200 mL Sucrose Solution. 
 
3. Chop the solution briefly in a homogenizer or polytron. **Do not sonicate! 
 
4. If cells are not pLyss, add 1 mg dry lysozyme per mL suspension (0.2 g) 
and stir for 10 minutes.  If cells are pLyss, just stir for 10 minutes. 
 
5. While stirring, add 500 mL Deoxycholate-Triton Solution.  Solution will 
become very viscous due to cell lysis and DNA release. 
 
6. Add 1 mL of 4 M MgCl2 Solution to make 5 mM final concentration. 
 
7. Add 2 mL DNAse Solution.  Stir until the solution is the viscosity of water. 
 
8. Freeze overnight at -20°C, or until ready to complete the prep. 
 
9. Thaw solution in warm water bath. 
 
10. Stir an additional 10 minutes after thawing to allow the DNAse to work 
again. 
 
11. Spin down in 2 centrifuge bottles at 8000 x g for 20 minutes. Discard 
supernatant. 
 
12. Re-suspend pellets in 300 mL or more each Triton Solution.  Chop briefly, 
keeping the pellets on ice as much as possible.  Spin down at 8000 x g for 
20 minutes and discard supernatant. 
 
13. Repeat step 12 three or more times. 
 
14. Re-suspend pellets into 300 mL or more each Tris-HCl Solution.  Chop 
briefly, keeping the pellets on ice as much as possible. Spin down at 8000 
x g for 20 minutes and discard supernatant. 
 
15. Repeat step 14 two or more times. 
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16. Re-suspend/dissolve the pellets and chop in ~200 mL Urea Solution. 
 
17. Spin down at 20°C, 15,000 x g for 30 minutes.  Filter through a 0.2 µm 
filter. 
 
18. Freeze at -70°C until ready to purify by Urea HQ. 
  
   
Subunit Purification: 
 
Column: HiTrap Q XL column, GE Healthcare 
Buffers:  A: 8 M urea, 20 mM Tris, 1 mM DTT 
  B: 8 M urea, 20 mM Tris, 1 M NaCl, 1 mM DTT 
   For α-subunits: pH 8.0 
          β-subunits: pH 9.0 
 
Preparing inclusion bodies: 
 
After urea solubilized inclusion bodies are thawed, adjust the pH of the b-subunit 
to 9.0. The β-subunits bound best at pH 9.0 on Applied Biosystem HQ column. 
 
1) Equilibrate the column with 1-5 column volumes of buffer A. 
 
2) Inject or load protein. 
 
3) Wash with at least 2-5 column volumes of buffer A. You’ll know it’s enough 
when the absorbance stabilizes again. 
 
4) Run a gradient from 0% B to 50% B (0-500 mM NaCl) over 10 column 
volumes. 
 
5) If there is more than one major peak eluting (as often is the case for β-
subunits), analyze fractions by SDS-PAGE or possibly by setting up test 
refoldings if you’re really nervous about it.  Usually all fractions of the majority 
peak of protein is β-subunit. 
 
6) Pool peak fractions. For β-subunits adjust the pH back to 8.0.  Add EDTA to a 
final concentration of 5 mM. Measure the concentration by UV absorbance scan 
against a urea (buffer A) blank.  For α-subunits: 1.3 OD280 nm = 1 mg/mL, and for 
β-subunits: 1.7 OD280 nm = 1 mg/mL.  Store in convenient aliquots at -80°C. 
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Notes: 
Components of the urea buffer (EDTA) seem to interfere with protein binding. 
Cleaning the column with 1 M NaCl/ 1 M NaOH after every couple of runs helps 
to regenerate the column capacity. However, column capacity becomes 
significantly lower with use, despite complex regeneration.  
 
The inclusion bodies give inconsistent, messy, broad looking chromatograms, but 
this purification is necessary to get rid of an unknown component that affects 
protein folding.  
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A.11. Preparation of Ab-Protein A Immunoaffinity Column 
Developed by Mia Rishe 
 
Materials: 
200 mM Borate: 1.24 g /100 mL, titrate to pH 9.0 with NaOH 
200 mM Ethanolamine: 1.2 mL/100 mL, titrate to pH 8.0 
Antibody solution, enough to have 10 mg/5 mL matrix 
Protein A-coupled matrix; IPA-400 Fast-Flow. 
PBS + 0.02% NaN3 
Dimethylpimelimidate (20 mM final, (MW=259), 5.18 mg/mL)   
Advice: Use a fresh bottle (e.g. unopened) every time 
 
Procedure: 
 
1) Mix Antibody and Protein A matrix in PBS, preferably with as small a volume 
as possible (ideally ~15 mL if using 5 mL matrix; can be scaled up 
accordingly).  This can be done in a polypropylene centrifuge tube, or directly 
in the gravity column body (just make sure the ends are sealed)  Rotate at 
room temperature 1 hour or longer.  Remove 15 mL of suspension into tube 
labeled “TOTAL”.  
 
2) Spin 2000 rpm 5 min, remove and save supernatant and pellet.  Or, if using 
the column, let the solution drain out.  Remove 15 mL of supernatant into tube 
labeled “NON-BOUND”.  
 
3) Resuspend pellet in 50 mL borate solution, spin/drain, remove supernatant. 
 
4) Resuspend pellet in 15 mL fresh borate solution.  Remove 10 mL into tube 
labeled “BOUND”.  Add 20 mM final dimethylpimelimidate as solid (77.7 mg 
for 15 mL) and dissolve.  Rotate 30 minutes at room temperature (going 
longer will over-couple the matrix) 
 
5) Spin/drain to remove supernatant and check that the pH of the supernatant is 
> 8.0. 
 
6) Resuspend pellet in 50 mL ethanolamine, rotate 30 minutes room 
temperature or longer, spin/drain off supernatant. 
 
7) Wash pellet with 50 mL ethanolamine, then 50 mL borate, then 50 mL PBS 
 
8) Resuspend pellet in 15 mL PBS.  Remove 15 mL of suspension into tube 
labeled “NON-COUPLED”.  Store matrix at 4°C in PBS + NaN3. 
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Analysis: 
 
Add 10 mL 2x Laemlli buffer to each fraction, boil, and spin in microfuge. 
Run 10% SDS-PAGE of MW markers, 1 mg mouse IgG, and 10 mL of each 
fraction taken.  Gel should show heavy and light chains in TOTAL and BOUND, 
and nothing in NON-BOUND and NON-COUPLED.  If there is more protein in 
NON-BOUND than BOUND, try a different binding buffer (PBS works fine for 
LB3.1/L243).  If there is any protein in NON-COUPLED, cycle the matrix through 
all binding and elution conditions that will be used in the affinity purification 
procedure, and next time use fresh pimelimidate! 
 
 
Sample of analysis gel: 
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A.12. Refolding and Purification of HLA-DR1 
Developed by M. Rushe 
 
Refolding of Subunits into Empty DR1: 
 
Refolding Mix: 
 25% glycerol 
 20 mM Tris-HCl, pH 8.5 
 1 mM EDTA 
 2 mM glutathione, reduced form 
 0.2 mM glutathione, oxidized form 
(glutathione should be added just before refolding) 
 
Anion exchange purified alpha and beta subunits solubilized in 8 M urea 
 
1) Chill refolding mix to 4°C before adding glutathione. Refolding should be 
performed in a container close to the volume of refolding to minimize 
exposure to air.  If desired, sparge the folding mix with argon for about 20 
minutes. 
 
2) Add glutathione and stir until just dissolved with a magnetic stirrer (about 30-
45 minutes). 
 
3) While rapidly stirring the folding mix, very slowly add purified subunits with a 
pipet. Add 2 mg of each subunit per 1 liter of refolding.  If refolding peptide-
loaded DR1, add 4 mg of each subunit and 5 M excess of peptide to the 
refolding mix assuming that 1 mg/L is the concentration of protein.   
 
4) After all components are well mixed, cover tightly and store at 4°C for at least 
36 hours. Week long refolding incubation tends to yield more complexes. 
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Immunoaffinity Purification of Empty Class II MHC from in vitro Folding 
Reactions: 
 
1) Concentrate folding mixture in the Amicon spiral filter concentrator 10 fold.  
Save the flow-through in case the filter membrane breaks.  If you routinely 
check the recovery with an ELISA, you will see if this happened by the 
presence of DR1 in the sample of flow-through you test.  
 
2) Exchange the folding buffer by filling the concentrator vessel (5 fold dilution) 
with PBS and concentrating.  Repeat this step two more times.  It is important 
to get rid of the glutathione in the folding mix or it will trash the immunoaffinity 
column! 
 
3) Flow the concentrated folding mix over the immunoaffinity column by gravity.  
The column is composed of the anti-MHC class II antibodies LB3.1 covalently 
coupled to Protein A. 
 
4) Wash with at least 10 column volumes of PBS. 
 
5) Pre-elute the column with at least two column volume 10 mM NaPi pH 7. 
 
6) There are two ways to elute.  Traditionally, the high pH method is used to 
elute class II from an immunoaffinity column.  
 
High pH: Elute the protein with 50 mM CAPS pH 11.5.  Collect 1 mL fractions into 
tubes containing 300 µl of 300 mM NaPi pH 6 (to neutralize).  About 5 column 
volumes should be sufficient. (Note: The lab experience is that the high pH 
method seems to yield more protein) 
 
Low pH: Elute the protein with 50 mM glycine pH 3.  Collect 1 mL fractions into 
tubes containing 300 µl of 300 mM Tris-HCl pH 8 (to neutralize).  About 5 column 
volumes should be sufficient. 
 
Prepare a “blank” (300 µl of 300 mM NaPi pH 6 plus 1 mL 50 mM CAPS pH 11.5, 
for example) to zero the spectrophotometer and also to check that the pH of the 
combined buffers is neutral. 
 
7) Neutralize the column with 300 mM NaPi pH 6 (if high pH elution was used), 
or 300 mM Tris pH 8 (if low pH elution was used). 
 
8) Wash column with at least 10 column volumes of PBS and 0.02% NaN3 and 
store in refrigerator. 
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9) Since the capacity of an immunoaffinity column varies greatly, you should 
repeat steps 1-7 with the “flow-through” until no more protein elutes from the 
column. 
 
10) To clean the column after you are finished: 
5 CV 50 mM CAPS pH 11.5                                                                                                 
5 CV 50 mM glycine pH 3                   
5 CV 50 mM CAPS pH 11.5          
5 CV 50 mM glycine pH 3                                                                                           
10-20 CV PBS/0.02% NaN3 
 
11) Pool the fractions containing DR1 based on their absorbance at 280 nm, 
concentrate and switch into a desired buffer (usually PBS). To avoid 
aggregation, store empty DR1 below 1 mg/mL. 
 
12) Check the prep for peptide binding activity: 
 
Incubate 5-10 µg DR1 with and without 5-molar excess HA peptide at 37°C for at 
least 48 hours.  
 
Example: 
DR1 stock 1 mg/mL                                                                                                             
+Ha sample:    no peptide sample: 
5 µl DR1     5 µl DR1 
2 µl 0.25 mM HA peptide    
13 µl PBS/0.02% NaN3                       15 µl PBS/0.02% NaN3 
 
final DR1 concentration: 0.25 µg/mL = 5 µM                                                                     
final peptide concentration: 25 µM 
 
Analyze by 12.5% SDS-PAGE: Run a boiled / not-boiled version of each sample 
Example: 
Add 5 µl of 5X reducing SDS sample buffer to each tube.  Load 12 µl into “non-
boiled” lane.  
Boil remaining 13 µl for 5 minutes and pulse in microfuge.  Load 12 µl into 
“boiled” lane. 
 
Ha-loaded class II should give a ~45 kDa band on an SDS gel that dissociates 
into α and β subunits when boiled.  “Empty” class II is not SDS stable and will 
dissociate into α and β subunits, for the boiled and not-boiled samples. You can 
further purify the immunoaffinity eluted empty class II MHC by size exclusion 
chromatography to obtain monomeric DR1.  There will be a lot of aggregated 
protein that elutes at a large molecular weight, but you should also see a peak at 
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~45 kDa corresponding to a class II αβ heterodimer.  The oligomeric distribution 
varies from prep-to-prep. 
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A.13. HLA-DR1 ELISA  
Protocol from Mia Rushe 
 
 
 
 
 
 
 
 
Materials: 
1. Block Solution: 3% BSA in PBSZ 
2. Dilution Solution:   0.3% BSA 
0.1% Triton X-100 
PBS (filter and store at 4°C) 
3. TBST:    25 mM Tris-HCl 
   137 mM NaCl 
   2.7 mM KCl 
   0.05% Triton X-100 
4.  Alternatively you can PBST instead of TBST:  PBS with 0.05% Triton X-
100. 
5.  ABTS solution:   5 mL 10X ABTS buffer (from Roche-made and frozen 
at -20°C in 5 mL aliquots) 
 45 mL ddH2O 
 1 ABTS tablet (from Roche also) 
 *Unused portion can be stored in dark at 4°C for 2 
weeks. 
 Or you can use the ready-to-use-ABTS solution that 
Roche sells!!! 
Protocol: 
 
1)  Coat 96-well plate with anti-DR monoclonal antibody LB3.1 (2 mg/mL 
stock in PBS + 0.02% NaN3).  Dilute 1:1000 in PBSZ and put 100 µL in 
each well.  Incubate at 37°C for 2 hours or 4°C overnight. 
 
2) Block plates with block solution for at least 4 hours at room temperature.  
(It is okay to store the plates in the cold room at this stage and use them 
later, they are good for about 3 weeks.) 
 
 
3) Put 50 µL of dilution solution in every well (It takes awhile to pipet samples 
and standards into wells to prevent them from drying out.)  
 
LB3.1 Ab
DR
CHAMP
Anti -­‐goat anti rabbit -­‐HRP
Substrate Measure Abs 405 nm
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4) Standards:  Do 2-fold dilutions in duplicate starting with 100 ng/ well:  100 
ng, 50, 25 , 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0.19, 0.1.  Dilute samples 
into dilution solution. (0.3% BSA, 0.1% Triton X-100, in PBS)  
  
5) Samples:  Put appropriate amount of sample on.  For tissue culture sup, 
put 50 and 5 µL (add and additional 45 µL tot eh wells that only 5µL of 
sample, so that you have 100 µL total in each well). 
 
6) Incubate standards and samples at 37°C for 1 hour or at room 
temperature for 2 hours or overnight at 4°C. 
 
7) Wash 3 times with PBST or TBST. (Be careful when washing the first 2 
times, you have different samples in each well and you don’t want the 
wells to spill into one another.) 
 
8) Add 100 µL/well of rabbit CHAMP diluted 1:25,000 in dilution solution.  
Incubate for 1.5  hours at room temperature or 1 hour at 37°C or overnight 
at 4°C. 
 
9) Wash wells 3 times with PBST or TBST. 
 
10) Add 100 µL/ well of goat anti-rabbit IgG-peroxidase diluted 1:4,000 in 
dilution solution.  It is very important that no azide is present in this step, it 
inhibits the HRP.  Incubate 0.5 to 2 hours at room temperature.  
(Background increases with if this step is left at 4°C overnight.) 
 
11) Wash wells 3 times with PBST or TBST. 
 
12) Add 200 µL of ABTS/ well and read absorbance at 405 nm. 
 
13) Work up data. 
ELISA fit-four 
equation used to fit data: 
line 1:   ((m1-m2)/(1+ (m0/m3)^m4)) + m2;  
inital guesses: m1=0.7; m2=0; m3=2; m4=-0.5  
partial derivatives: 
line 2:   1/(1+(m0/m3)^m4) 
line 3:   1-(1/(1+(m0/m3)^m4)) 
line 4:   (m1-m2)*(1+(m0/m3)^m4)^(-2)*(m4*(m0/m3)^(m4-1))*m0/m3^2 
line 5:    (m2-m1)*(1+(m0/m3)^m4)^(-2)*(m0/m3)^m4*ln(m0/m3) 
inverse fit-four 
c1=m3*((m1-m2)/(c0-m2)-1)^(1/m4) 
an alternate equation for fitting ELISA data 
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A.14. Expression and Purification of the Superantigen, SEC3-3B2 
Protocol by Zarixia Zavala-Ruiz 
 
Expression: 
1) Several dilutions of 15 mL culture were grown overnight (2xYT media, 100 
µg/mL ampicillin, 2% glucose) at 37°C. 
2) Fifteen mL were used to inoculate two 2 L flask (each containing 500 mL 
of 2xYT media and 100 µg/mL ampicillin).  Cells were grown for about 2-4 
hours at 37°C until OD600 was about 1 (you can induce when OD600 is 
anywhere between 0.8-1.2) 
3) Cells were induced for about 5hrs (induction can be between 4-6 hrs). 
4) Cells were spin down at 5000 rpm for 15 minutes. 
5) The cells were resuspended in 10 mLs of ice-cold TES buffer (100 mLs of 
TES buffer:  3.15 g of Tris-HCl, 0.186 g of EDTA, 17.1 g of sucrose, pH 
8.0).  Suspension was left at 4°C overnight.  Alternatively, it can be 
incubated on ice for 1 hour. 
6) Next day, 15 mL of ice-cold 0.2x TES buffer were added to the suspension 
and left on ice for 45 minutes (should not be left on ice for more than 1 hr).   
7) Cells were spin down for 10 minutes at 7000 rpm. 
8) The supernatant was transferred to a reusable tube and it was spin for 20 
minutes at 12000 rpm.  
9) The yellowish liquid was dialyzed against 2 L of 20 mM Tris-HCl pH 7.5 for 
~8 hrs at 4°C.  Fresh buffer was used to dialyze overnight. 
Red-A purification: 
1) Approximately 6 mL of Red-A agarose were transferred to a low-pressure 
column. 
2) It was washed with 2 CV of 0.5M NaOH, 6 M Urea to remove excess dye 
(this step is only done when the resin is new). 
3) Column was equilibrated using 10 CV of 20 mM Tris-HCl pH 7.5. 
4) Protein was added slowly, and the flow through was collected. 
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5) Column was washed with 50 mL of 20 mM Tris-HCl pH 7.5. 
6) The protein was eluted with 25 mL of 20 mM Tris-HCl, 0.5 M NaCl pH 7.5.  
(Fractions of 5 mL were collected) 
7) The column was regenerated using 25 mL of 0.5 M NaOH, 6 M Urea. 
8) Column was stored in water + 0.02% azide. 
9) Fractions were checked on an SDS gel. 
10) Protein buffer was exchanged to 20 mM Tris-HCl pH 8.5 for ion-exchange 
purification. 
 
Ion-exchange-purification: 
1) Mono Q purification was performed using 20 mM Tris-HCl pH 8.5 as buffer 
and eluting with 1 M NaCl. 
2) The protein comes out at about 30% NaCl.  Fractions are checked, and 
the buffer is exchange to 10 mM Tris-HCl pH 7.5 for crystallization. 
Note: Using HQ, the protein will come out 85-90% pure, with Mono-Q is 95% 
pure.  Purity is important for crystallographic purposes. 
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A.15. Expression and Purification of the T cell Receptor, AC25scTCR 
 
 
Expression: 
10) Several dilutions of 15 mL culture were grown overnight (2xYT media, 100 
µg/mL Chloramphenical, 2% glucose) at 27°C. 
11) Fifteen mL were used to inoculate two 2 L flask (each containing 500 mL 
of 2xYT media and 100 µg/mL Chloramphenical).  Cells were grown for 
about 2-4 hours at 27°C until OD600 was about 1 (you can induced when 
OD600 is anywhere between 0.8-1.2) 
12) Cells were induced for about 5 hrs (induction can be between 4-6 hrs). 
13) Cells were spin down at 5000 rpm for 15 minutes. 
14) The cells were resuspended in 10 mL of ice-cold TES buffer (100 mL of 
TES buffer:  3.15 g of Tris-HCl, 0.186 g of EDTA, 17.1 g of sucrose, pH 
8.0).  Suspension was left at 4°C overnight.  Alternatively, it can be 
incubated on ice for 1 hour. 
15) Next day, 15 mL of ice-cold 0.2x TES buffer were added to the suspension 
and left on ice for 45 minutes (should not be left on ice for more than 1 hr).   
16) Cells were spin down for 10 minutes at 7000 rpm. 
17) The supernatant was transferred to a reusable tube and it was spin for 20 
minutes at 12000 rpm.  
18) The yellowish liquid was dialyzed against 2 L of 20 mM Tris-HCl pH7.5 for 
~8 hrs at 4°C.  Fresh buffer was used to dialyze overnight. 
 
Purification of AC25scTCR for Crystallization with HIS tag 
NiNTA purification: 
1. Equilibrate NiNTA (Qiagen) with 3-5 CV 20mM Tris-HCl pH 7.5 
2. Bind equilibrated AC25scTCR sample onto column. Save flow through. 
3. Wash with 1-2 CV 20 mM Tris-HCl pH 7.5. Collect wash. 
4. Elute with 5 CV 20 mM Tris-HCl pH 7.5 with 10 mM imidazole.  
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5. Elute with 5 CV 20 mM Tris-HCl pH 7.5 with 30 mM imidazole.  
6. Elute with 5 CV 20mM Tris-HCl pH 7.5 with 100 mM imidazole.  
7. Elute with 2 CV 20mM Tris-HCl pH7.5 with 300 mM imidazole. 
8. Run SDS PAGE gel of wash, flow through and fractions. 
9. Pool fractions and concentrate for gel filtration. 
 
Gel Filtration can be done with Superdex S200 in PBS  
1. Filter samples before injection and be sure that all solutions are degassed 
and filtered. 
2. Run SDS PAGE to determine which fractions to pool  
3. Pool fractions, buffer exchange to 10 mM Tris-HCl pH 7.5 and concentrate 
to at least 10 mg/mL for crystallization. 
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A.16. ERAP1 Protein Construct 
 
 
Sequence  
 
1   MVFLPLKWSL ATMSFLLSSL LALLTVSTPS WCQSTEASPK RSDGTPFPWN KIRLPEYVIP 
61  VHYDLLIHAN LTTLTFWGTT KVEITASQPT STIILHSHHL QISRATLRKG AGERLSEEPL 
121 QVLEHPRQEQ IALLAPEPLL VGLPYTVVIH YAGNLSETFH GFYKSTYRTK EGELRILAST 
181 QFEPTAARMA FPCFDEPAFK ASFSIKIRRE PRHLAISNMP LVKSVTVAEG LIEDHFDVTV 
241 KMSTYLVAFI ISDFESVSKI TKSGVKVSVY AVPDKINQAD YALDAAVTLL EFYEDYFSIP 
301 YPLPKQDLAA IPDFQSGAME NWGLTTYRES ALLFDAEKSS ASSKLDITMT VAHELAHQWF 
361 GNLVTMEWWN DLWLNEGFAK FMEFVSVSVT HPELKVGDYF FGKCFDAMEV DALNSSHPVS 
421 TPVENPAQIR EMFDDVSYDK GACILNMLRE YLSADAFKSG IVQYLQKHSY KNTKNEDLWD 
481 SMASICPTDG VKGMDGFCSR SQHSSSSSHW HQERVDVKTM MNTWTLQRGF PLITITVRGR 
541 NVHMKQEHYM KGSDGAPDTG YLWHVPLTFI TSKSDMVHRF LLKTKTDVLI LPEEVEWIKF 
601 NVGMNGYYIV HYEDDGWDSL TGLLKGTHTA VSSNDRASLI NNAFQLVSIG KLSIEKALDL 
661 SLYLKHETEI MPVFQGLNEL IPMYKLMEKR DMNEVETQFK AFLIRLLRDL IDKQTWTDEG 
721 SVSERMLRSE LLLLACVHNY QPCVQRAEGY FRKWKESNGN LSLPVDVTLA VFAVGAQSTE 
781 GWDFLYSKYQ FSLSSTEKSQ IEFALCRTQN KEKLQWLLDE SFKGDKIKTQ EFPQILTLIG 
841 RNPVGYPLAW QFLRKNWNKL VQKFELGSSS IAHMVMGTTN QFSTRTRLEE VKGFFSSLKE 
901 NGSQLRCVQQ TIETIEENIG WMDKNFDKIR VWLQSEKLEH DPEADATGLE RMLESRGPFE 
961 QKLISEEDLN MHTEHHHHHH  
 
Expected Molecular Weight: 111964.8 Daltons 
 
Expected Extinction Coefficient at 280 nm: 171,200 M-1 cm-1 
 
Protein pI: 5.84 
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A.17. HLA-DR1 Protein Construct 
 
Sequence  
 
Alpha-Chain 
1   MIQEEFKMIK EEHVIIQAEF YLNPDQSGEF MFDFDGDEIF HVDMAKKETV WRLEEFGRFA 
61  SFEAQGALAN IAVDKANLEI MTKRSNYTPI TNVPPEVTVL TNSPVELREP NVLICFIDKF  
121 TPPVVNVTWL RNGKPVTTGV SETVFLPRED HLFRKFHYLP FLPSTEDVYD CRVEHWGLDE 
181 PLLKHWEFDA END 
 
 
Beta-Chain 
1   MIQEEFKMGD TRPRFLWQLK FECHFFNGTE RVRLLERCIY NQEESVRFDS DVGEYRAVTE  
61  LGRPDAEYWN SQKDLLEQRR AAVDTYCRHN YGVGESFTVQ RRVEPKVTVY PSKTQPLQHH 
121 NLLVCSVSGF YPGSIEVRWF RNGQEEKAGV VSTGLIQNGD WTFQTLVMLE TVPRSGEVYT 
181 CQVEHPSVTS PLTVEWRAEN D 
 
 
Expected Molecular Weight:  
Alpha-Chain: 22,528.5 Daltons 
Beta-Chain : 23,449.2 Daltons 
 
 
Expected Extinction Coefficient at 280 nm:  
Alpha-Chain: 28,085 M-1 cm-1 
Beta-Chain: 39,420 M-1 cm-1 
 
Protein pI:  
Alpha-Chain: 4.67 
Beta-Chain: 5.47 
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A.18. Superantigen, SEC3-3b2, Protein Construct 
 
 
Sequence  
 
1   MESQPDPMPD DLHKSSEFTG TMGNMKYLYD DHYVSATKVK SVDSFFKWDL IYNISDKKLK 
61  NYDKVKTELL NEDLAKKYKD EVVDVYGSNY YVNCYFSSKD NVGKVTGGKT CMYGGITKHE 
121 GNHFDNGNLQ NVLVRVYENK RNTISFEVQT DKKSVTAQEL DIKARNFLIN KKNLYEFNSS 
181 PYETGYIKFI ENNGNTFWYD MMPAPGDKFD QSKYLMMYND NKTVDSKSVK IEVHLTTKNG  
 
Expected Molecular Weight: 27,814.2 Daltons 
 
Expected Extinction Coefficient at 280 nm: 37945 M-1 cm-1 
 
Protein pI: 6.53 
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A.19. AC25 single chain T cell receptor Protein Construct 
 
 
Sequence  
 
1   MKYRGQILLP TAAAGLLLLA AQPAMADSVT QLDSQVPVFE EAPVELRCNY SSSVSVYLFW  
61  YVQYPNQGLQ LLLKYLSGST LVKGINGFEA EFNKSQTSFH LRKPSVHISD TAEYFCAVSP  
121 RSNTGKLIFG QGTTLQVKPG GGGSGGGGSG GGGSGGGGSM GVTQTPKHLI TATGQRVTLR  
181 CSPRSGDLSV YWYQQSLDQG LQFLIQYYNG EERAKGNILE RFSAQQFPDL HSELNLSSLE  
241 LGDSALYFCA SSPRTGAGSD TQYFGPGTRL TVLAASGADH HHHHH 
 
 
Expected Molecular Weight: 30485.1 Daltons 
 
Expected Extinction Coefficient at 280 nm: 30,370 M-1 cm-1 
 
Protein pI: 7.28 
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